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Abstract: 2’3’-cGAMP is an uncanonical cyclic dinucleotide where one A and one G base are connected via a 3’-5’ and a unique 2’-5’ linkage. 
The molecule is produced by the cyclase cGAS in response to cytosolic DNA binding. cGAMP activates STING and hence one of the most 
powerful pathways of innate immunity. cGAMP analogs with uncharged linkages that feature better cellular penetrability are currently highly 
desired. Here, we report the synthesis of a cGAMP analog with one amide and one triazole linkage. The molecule is best prepared via a first 
Cu(I) catalysed click reaction which establishes the triazole, while the cyclization is achieved by macrolactamization. 
Introduction 
Cyclic dinucleotides (CDNs) are important cellular messenger molecules in a variety of organisms.[1] The compounds play a crucial role 
in a wide range of biological processes, such as signal transduction, control of biofilm formation or quorum sensing. [2] Bacteria produce 
molecules in which two purine bases are linked via two 3’-5’ phosphate linkages to give symmetrical cyclophane structures.[3] One main 
example for such a molecule is the c-di-GMP compound 1 shown in Fig. 1.[4,5] Biochemically the compound is generated from the 
corresponding nucleotide-5’-triphosphates. Recently, an unsymmetrical cyclic dipurine molecule (cGAMP, 2) was discovered in 
mammalian cells.[6,7] In this molecule, the two purines are connected via one 3’-5’ and another 2’-5’ linkage.[8] The dinucleotide 2 is 
assembled by the cyclase cGAS (cyclic GMP-AMP synthase). cGAS is a cytosolic DNA sensor and part of the innate immune 
system.[9,10] 2’3’-cGAMP (2) binds to the transmembrane receptor STING (stimulator of interferon genes) with nanomolar affinity 
(kd = 4.59 nM),[11] which activates the type 1 interferon (IFN) pathway.[12-14] Subsequent degradation of cGAMP 2 occurs by the specific 
cleavage of the 2’-5’ phosphodiester bond by ENPP1 highlighting the importance of this unusual connection.[15,16] 
There is currently tremendous interest to develop synthetic routes towards analogs of cGAMP 2 as potential agonists or antagonists 
for cGAS and STING.[17-19] The bisphosphorothioate cGAMP derivative 3,[20,21] for example, is already in clinical trials.[22,23] Alternative 
targeting of STING with small molecules is also known.[24-26] Particularly, compounds which lack the negatively charged phosphodiester 
linkages are discussed as new immune-regulatory pharmaceuticals.[27] While such derivatives are available for symmetric 3’-5’ 
dinucleotides[28-32], to the best of our knowledge, uncharged cGAMP 2 analogs do not exist. 
In this article, we describe the modular synthesis of a neutral cGAMP analog 4 that features one triazole and one amide linkage. The 
triazole was generated by a Cu(I) catalysed alkyne-azide click reaction (CuAAC) that was found to be particularly efficient on nucleotides 
and oligonucleotides.[33-35] 
  
 
 
Figure 1: Depiction of the symmetrical microbial c-di-GMP 1, the unsymmetrical STING activator cGAMP 2, as well as the 
bisphosphorothioate analog 3, together with the molecule 4 targeted here. AL = amide linked, TL = triazole linked. 
Results and Discussion 
We decided to start our synthetic study by synthesizing the cGAMP analog 4, in which the 5’-G-3’-A linkage is replaced by a triazole 
unit and the 2’-G-5’-A linkage is substituted by an amide bond.  
Molecular modeling (Fig. 2) showed that the analog 4 is able to adopt a conformation that is similar to the natural ligand bound to 
STING.[11,36] 
 
Figure 2: 3D representation showing the potential conformational similarity between compound 4 (left) and natural 2’3’-cGAMP (right, 
conformation of 2 bound to STING, PDB: 4LOH). 
 
In both cases, the macrocycle is thought to force the bases into a shifted parallel orientation with the imidazole part of the nucleobases 
pointing towards each other. This requires anti-conformations of both glycosidic bonds. The preferred conformation of compound 4 will 
be governed by aromatic the triazole unit. For the conformation of the amide we assume a syn-conformation due to the small ring size. 
  
 
Analysis of potential synthetic accesses of 4 shows that it can be generated by Cu(I) catalyzed azide alkyne reaction plus a preceding 
or following lactamization. We developed the synthesis based on the A-half 5 and the corresponding G-half 6 as depicted in Fig. 3. For 
the synthesis of the A-half 5, we started with the commercially available 1,2-acetonide protected xylofuranoside 7 (two steps from D-
xylose), which we converted in three steps into the 5-TBS-1,2-acetonide protected 3-methylene xylofuranoside 8. 
 
Figure 3: Synthetic strategy towards compound 4. dpc = diphenylcarbamoyl, iBu = isobutyryl. 
 
After stereoselective hydroboration (BH3·DMS, dr: 9:1) of 8 and Swern oxidation, we obtained the carbonyl compound 9, which we 
subjected to a Corey-Fuchs alkinylation (CBr4, BuLi). TBS deprotection and conversion of the primary hydroxyl group into the azide 
gave the key intermediate 10. X-ray analysis of the structure of 10 proved the right configuration of the compound (recrystallisation 
from isohexanes/ethyl acetate). 
 
Scheme 1: Synthesis of the A-half 5 in 14 steps. a) TBSCl, Py, RT, 2h, 97%; b) (COCl)2, DMSO, NEt3, DCM, -60°C, 3h; c) CH3PPh3Br, 
BuLi,  THF, RT, 6h, 81% (over two steps); d) BH3·DMS, THF, RT, 12h then 30% H2O2, 2N NaOH, RT, 2h, 76%; e) (COCl)2, DMSO, 
NEt3, DCM, -60°C, 3h, 93%; f) CBr4, PPh3, DCM, 0°C, 1h then RT, 12h, 85%; g) BuLi, THF, -78°C, 1.5h, 83%; h) TBAF, THF, RT, 4h, 
95%; i) TsCl, Py, RT, 18h, 87%; j) NaN3, DMF, 80°C, 3h, 94%; k) HOAc/Ac2O, H2SO4 (cat.), RT, 5h, 78%; l) 6-N-Benzoyladenine, BSA, 
TMSOTf, DCE, 80°C, 4h, 61%; m) PMe3, H2O, THF, 40 °C, then RT, 12h, 66%; n) Boc2O, NEt3, DCM, RT, 16h, 64%. Overall yield 
starting from 7: 6% 
 
  
 
Subsequent cleavage of the isopropylidene group and acetyl protection of the hydroxyl groups provided compound 11, which was the 
sugar building block for the following glycosylation step. The Vorbrüggen reaction to 12 was found to be most efficient under 
BSA/TMSOTf conditions with a benzoyl protected A-heterocycle (α/β: 1:12). Finally, we converted the azide via a Staudinger reduction 
(PMe3 worked better than PPh3) into the corresponding amine, which was Boc-protected afterwards to give the A-half 5. 
 
Scheme 2. Synthesis of the G-half 6 in 13 steps. a) AcCl, BnOH, 60°C, 5h, 80%; b) Me2C(OMe)2, Me2CO, p-TsOH (cat.), 60°C, 2h, 
84%; c) (COCl)2, DMSO, NEt3, DCM, -60°C, 3h; d) Ph3PCHCO2Et, DCM, RT, 12h, 86% (over two steps); e) H2, Raney-Ni, EtOH, RT, 
20h, 90%; f) H2, Pd/C, EtOH/THF, 36h, 88%; g) 80% HOAc, RT, 24h; h) H2SO4 (cat.), MeOH, 4°C, 3d, 72% (over two steps); i) TsCl, 
Py, RT, 18h, 76%; i) NaN3, DMF, 80°C, 3h, 75%; k) BnBr, KOH, THF, reflux, 5h, 91%; l) HOAc/Ac2O, H2SO4 (cat.), RT, 3h, 85%; m) 
6-O-(Diphenylcarbamoyl)-2-N-isobutyrylguanine (Gdpc/iBu), BSA, TMSOTf, DCE, 80°C, 2h, 72%. Overall yield starting from 13: 10%. 
 
The desired G-half (Scheme 2) was synthesized starting from D-arabinose (13). 1-O-Benzyl and 3,4-acetonide protection yielded 
alcohol 14. 
Subsequent Swern oxidation and Wittig homologation provided the intermediate 15 (E/Z: 4:1). Employing the acetonide protective 
group as a stereoselective directing group, compound 16 was almost exclusively obtained in R-configuration via a Raney-Ni-assisted 
hydrogenation (dr: 20:1). 
Under these reduction conditions the 1-O-benzyl group remained unaffected – keeping the sugar in its pyranoside configuration. 
Removal of the protective groups and treatment with catalytic amounts of acid furnished at 4 °C selectively the ribofuranoside 17. This 
was followed by an in situ lactonization. The resulting alcohol 17 was tosylated and reacted with NaN3 to give azide 19. The absolute 
configuration of the compounds was again proven with a crystal structure of 18 (SI). 
We subsequently opened the lactone ring to compound 20 via hydroxide-mediated benzyl protection and converted it into its 1-O-acetyl 
derivative 21. The glycosylation reaction to the G-half 6 was performed by a so far unreported Vorbrüggen pattern in high β-selectivity 
(α/β: 1:14) and good yields (79%). 
The assembly of nucleoside building blocks A (5) and G (6) was initiated by a CuAAC reaction. This reaction went smoothly and 
provided the dinucleotide 22 in fair yield of 80% (Scheme 3). We noticed that click-approaches with the Boc-deprotected amine 
compound A gave rise of several side products as monitored by thin-layer chromatography (TLC). 
 
  
 
Scheme 3. The assembly towards cyclic dinucleotide 4 in 6 steps. a) CuSO4, Na-Ascorbate, THF/tBuOH/H2O, RT, 24h, 80%; b) 
TFA/DCM (1:1), 0°C, 1h, 81%; c) H2, Pd/C, EtOH, 36h; d) HATU, DIPEA, DMF (1mM), RT, 24h, 52% (over two steps); e) BCl3, DCM, 
-40°C, 3d; f) NH3, H2O/MeOH, 50°C, 20h, 48% (over two steps). Overall yield starting from 5 and 6: 16%. 
 
TFA treatment of dinucleotide 22 resulted in the cleavage of both the Boc and the diphenylcarbamoyl (dpc) group. Besides, this was 
the last step of the consecutive synthesis where purification could be easily conducted by flash column chromatography (DCM/MeOH, 
10:1) due to the increasing polarity of the following compounds. A palladium catalyzed hydrogenation reaction deprotected the benzyl 
ester by leaving the secondary 3’’’’-O-benzyl ether intact. Final macrolactamization with HATU furnished the cyclized dinucleotide 24. 
Deprotection of the 3’’’’-O-benzyl ether under BCl3/DCM conditions (-40°C) proved to be the best option even though solubility in organic 
solvents decreased with ongoing removal of protective groups. Final ammonolysis revealed our target molecule 4 in 2% overall yield 
starting from the G-pathway (19 steps) and 1% starting from the A-pathway (20 steps), respectively. Compounds 24, 25 and 4 were 
purified by RP-HPLC and subjected to further NMR-studies. 
 
 
Figure 4: NOESY spectrum of the final compound 4 in DMSO-d6 
  
  
 
Conformational Analysis and Conclusion 
We performed detailed NOESY experiments in order to determine the conformation preferences of target compound 4 in respect to 
potential STING binding. The spectrum is shown in Fig. 4. The most informative NOE contacts together with a depiction of the modelling 
results of 4 in solution is shown in Fig. 5. The NMR data confirm the overall structure with two β-configured glycosidic bonds both in 
anti-conformation. Most interesting, however, is the large shielding of proton H-2’’’’, which shifts from (compound 23) = 4.12 ppm to 
(compound 4) = -0.47 ppm. This dramatic shift indicates that the proton is positioned just on top of the aromatic triazole ring. 
 
 
 
 
 
 
Figure 5: Selected NOE contacts of compound 4 (in DMSO-d6) and modelling of the preferred conformation based on the NOE data. 
 
According to this low chemical shift, it is assumed that H-2’’’’ points directly to the triazole ring within the cyclized structures of 
compounds 24, 25 and 4. Unraveling of the conformation just based on the NOE data shows that compound 4 likely adopts a more 
open conformation in solution (DMSO-d6) compared to cGAMP 2, with the two heterocycles being not parallel to each other. 
 
Potential binding of compound 4 to STING was tested in vitro by nanoDSF assays and analysis of thermal unfolding of the STING 
constructs hSTING_L139 (human STING AA139-379) and mSTING_L138 (mouse STING AA138-378). We used the physiological 
ligand 2′3′-cGAMP and a ligand with lower affinity, 3′3′-cGAMP, as positive controls. As expected after the conformational analysis of 
compound 4, binding to hSTING or mSTING could not be detected. This result was confirmed with ITC experiments (see supporting 
information). Based on the more open structure of the here prepared compound 4, we believe that interaction studies with cGAS or 
ENPP1 may be more promising. Investigations in this direction are on the way. 
 
In summary, we report the first synthesis of a 2’3’-cGAMP analog which features uncharged bridges that should provide membrane 
crossing properties. The synthetic strategy involved first linking of the two nucleotides by a Cu(I)-catalyzed click reaction followed by a 
macrolactamization to close the cycle. The synthesis of medium size ring structures is always difficult. We believe that the here 
described strategy will open the access to a variety of derivatives of 4. This allows systematic scanning of the conformational space of 
the two nucleobases relative to each other regarding the binding to the involved proteins STING, cGAS and ENPP1. 
Experimental Section 
Unless otherwise specified, all reactions were magnetically stirred under an N2 atmosphere. Reaction vessels were dried under high vacuum at 550 °C 
prior to use. Dry solvents and reagents were purchased from commercial suppliers, such as Sigma-Aldrich, Acros Organics, Carbosynth, TCI Europe, 
ABCR, VWR, stored under septum over molecular sieves and used as received. The reaction progress and fractions during column chromatography 
were monitored by TLC on silica gel 60-F254 plates purchased from Merck and visualized by irradiation with UV-light (254 nm or 366 nm) and p-
anisaldehyde staining solution (p-anisaldehyde (3.7 mL), EtOH (135 mL), conc. H2SO4 (5 mL), conc. AcOH (1.5 mL)). Purification was performed using 
flash column chromatography with silica gel (Merck, particle size 0.063 – 0.200 mm). The eluents used were determined by TLC. Purification of the crude 
dinucleotides 24, 25 and 4 was operated by Waters 2695 reversed phase high performance liquid chromatography (RP-HPLC) using Nucleosil columns 
(250/4 mm, C18ec, particle size 3 μm for analysis or 250/10 mm, C18ec, 5 μm for purification) from Machery-Nagel with a bufferfree H2O/MeCN eluent 
system. Water was purified by a Milli-Q Plus system from Merck Millipore. NMR-spectra were measured on a Bruker Ascend 400 or Bruker ARX 600 at 
room temperature operating at 400 MHz or 600 MHz for 1H-nuclei and at 101 MHz or 151 MHz for 13C-nuclei. The chemical shift (δ) in the NMR-spectra 
is reported in parts per million (ppm) and referenced by the residual solvent signal. Measurements were performed in CDCl3 and DMSO-d6. The spectra 
were referenced to the residual protons and carbons of the solvent (CHCl3: δ(1H) =7.26 ppm, δ(13C) = 77.16 ppm; DMSO-d6: δ(1H) =2.50 ppm, 
δ(13C) = 39.52 ppm). Proton-spectra also show the integral intensity, the multiplicity, abbreviated with s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet) and the coupling constant (J in Hz). Assignments of the signals were performed using 2D-NMR techniques such as homonuclear correlation 
spectroscopy (COSY), nuclear Overhauser effect spectroscopy (NOESY), heteronuclear single quantum coherence (HSQC) and heteronuclear multiple 
bond coherence (HMBC). All spectra were analysed with the software MestReNOVA 10.0 from Mestrelab Research S. L. Atom labelling and nomenclature 
are not in correspondence with IUPAC. High resolution mass spectra (HRMS) were measured on a Thermo Finnigan MAT 95 (EI) and a Thermo Finnigan 
LTQ FTICR (ESI). IR-measurements were performed on a Perkin Elmer Spectrum BX FT-IR spectrometer with a diamond-ATR (Attenuated Total 
Reflection) setup. Uncorrected melting points were determined with an automated Stanford Research Systems EZ-Melt apparatus (digital image 
processing technology). Samples were loaded in open capillary tubes. X-ray crystallography of single crystals was performed on an Oxford XCalibur 
  
 
diffractometer and further analysis by the software Ortep-3.[37] The structure of the synthesized analog 4 in Fig. 2 was obtained using the geometry 
optimization tool of the open source software Avogadro and visualized by PyMol. 
 
Nano differential scanning fluorimetry (nanoDSF): Thermal melting experiments of STING constructs were performed using a Tycho NT.6 instrument 
(NanoTemper Technologies). In brief, the samples were heated up in a glass capillary and while heating, the internal fluorescence at 330 nm and 350 
nm was recorded. Data analysis, data smoothing and calculation of derivatives was done using the internal evaluation features of the NT.6 instrument. 
All measurements were repeated to confirm robustness of the assay. 
 
Isothermal titration calorimetry: ITC experiments were performed using a Malvern PEAQ-ITC system with 20 µM protein in ITC-buffer (20 mM HEPES 
pH = 7.5, 150 mM NaCl) in the cell. The positive controls of cGAMP ligands (Biolog) were titrated in a concentration of 200 µM into the cell by 19 injections 
of 2 µL, spaced 150 s apart, at 25°C. Compound 4 was used in a concentration of 291 µM for titration. The results were analyzed using the MicroCal 
PEAQ-ITC analysis software provided with the instrument. All titrations were repeated to confirm robustness of the assay. 
 
Cloning, Expression and Purification: Human STING AA139-379 and mouse STING AA138-378 constructs were cloned according to previous 
studies.[38] The plasmids were used to transform E. coli Rosetta (DE3) protein expression strain cells (Novagen). The cells were grown in 1 L of Turbo 
Broth™ media (Molecular Dimensions) supplemented with Kanamycin (50 mg/L) and Chloramphenicol (34 mg/L) at 37°C to an OD600=1.3 and expression 
was induced by adding IPTG to a final concentration of 0.2 mM. Purification of the STING constructs has been performed as described previously.[38] 
 
5-O-(tert-Butyldimethylsilyl)-3,3-deoxymethylene-1,2-O-isopropylidene-α-D-xylofuranose (8): The title compound was prepared according to a 
modified procedure of Betkekar et al.[39] To a solution of oxalyl chloride (12.3 mL, 17.9 g, 141 mmol, 1.10 eq.) in dry DCM (450 mL) was slowly added 
DMSO (20.0 mL, 22.0 g, 282 mmol, 2.20 eq.) under N2 at -78 °C. The temperature was maintained below -60 °C and evolving gas was purged. After the 
mixture was stirred for 1 h at -60 °C, a solution of 5-O-(tert-butyldimethylsilyl)-1,2-O-isopropylidene-α-D-xylofuranose[40] (39.0 g, 128 mmol, 1.00 eq.) in 
dry DCM (125 mL) was added to the reaction mixture over 5 min and stirred for 2 h. Triethylamine (53.6 mL, 38.9 g, 384 mmol, 3.00 eq.) was added and 
the suspension was stirred for a further hour at -60 °C. The reaction mixture was warmed to RT, quenched with saturated aqueous NaHCO3 (200 mL) 
and extracted with DCM (3x200 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo to obtain 5-O-
(tert-butyldimethylsilyl)-3-oxo-1,2-O-isopropylidene-α-D-xylofuranose[41] as a waxy yellow solid. The compound was used in the next step without further 
purification. 
Methyl triphenyl phosphonium bromide (86.2 g, 241 mmol, 2.00 eq.) was suspended in THF (360 mL) and cooled to -78 °C under N2. n-Butyl lithium 
(96.5 mL, 241 mmol, 2.5M in hexanes, 2.00 eq.) was carefully added dropwise and the resulting red suspension (LiBr precipitates) was stirred for 1 h at 
0°C. Subsequent addition of a solution of the crude ketone (36.5 g, 121 mmol, 1.00 eq.) in THF (60 mL) over 10 min gave a slurry which was stirred at 
RT for 6h. The reaction mixture was quenched with saturated aqueous NH4Cl (50 mL) and then extracted with ethyl acetate (3 x 200 mL). The combined 
organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash-column chromatography 
(silica gel, isohexanes/EtOAc, 9:14:1) to yield compound 8 as a colorless syrup (31.1 g, 104 mmol, 81% over 2 steps). Rf = 0.68 (silica, 
isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2930, 1463, 1372, 1252, 1071, 1018, 775 cm-1. 1H NMR, COSY (400 MHz, CDCl3): δ = 5.85 (d, 3J = 4.1 Hz, 1H, 
H-1), 5.42 (dd, 4J = 2.2 Hz, 4J = 1.1 Hz, 1H, C=CHa), 5.26 (m, 1H, C=CHb), 4.88 (dd, 3J = 4.1 Hz, 4J = 1.4 Hz, 1H, H-2), 4.75 (ddd, 3J = 4.2 Hz, 3J = 3.8 
Hz, 4J = 2.2 Hz, 1H, H-4), 3.75 (dd, 2J = 10.6 Hz, 3J = 4.2 Hz, 1H, Ha-5), 3.67 (dd, 2J = 10.6 Hz, 3J = 3.8 Hz, 1H, Hb-5), 1.49 (s, 3H, C(CH3)2), 1.38 (s, 3H, 
C(CH3)2), 0.87 (s, 9H, SiC(CH3)3), 0.043 (s, 3H, Si(CH3)2), 0.040 (s, 3H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 147.7 (C-3),112.6 
(C(CH3)2), 111.7 (C=CH2), 105.1 (C-1), 82.1 (C-2), 81.0 (C-4), 65.9 (C-5), 27.7 (C(CH3)2), 27.5 (C(CH3)2), 26.0 (SiC(CH3)3), 18.4 (SiC(CH3)3), -5.24 
(Si(CH3)2), -5.31 (Si(CH3)2) ppm. ESI-HRMS calcd. for [C15H28O4Si + NH4]+ 318.2095, found: 318.2098. 
 
5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-(hydroxymethyl)-1,2-O-isopropylidene-α-D-ribofuranose (9a): The title compound was prepared according 
to a modified procedure of Betkekar et al.[39] To a solution of vinyl compound 8 (29.5 g, 98.2 mmol, 1.00 eq.) in dry THF (300 mL) was added borane 
dimethyl sulfide complex (73.6 mL, 147 mmol, 2M in THF, 1.50 eq.) at 0 °C. After the solution was stirred for 12 h at RT, aqueous 2 N NaOH (225 mL) 
was carefully added under strong gas evolution at 0 °C to give a turbid suspension. The reaction mixture was treated slowly with 30% aqueous hydrogen 
peroxide (98.0 mL) at the same temperature to avoid heat development. The suspension was stirred for further 2 h at RT, quenched with saturated 
aqueous Na2S2O3 solution (200 mL) at 0 °C and finally extracted with EtOAc (3 x 300 mL). The combined organic layers were washed with brine, dried 
over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by flash-column chromatography (silica gel, 
isohexanes/EtOAc, 4:12:11:1) to afford alcohol 9a (23.8 g, 74.7 mmol, 76%) as a colorless oil. Rf = 0.76 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 
3456, 2931, 1463, 1381, 1253, 1105, 1019, 778 cm-1. 1H NMR, COSY (400 MHz, CDCl3): δ = 5.79 (d, 3J = 3.7 Hz, 1H, H-1), 4.75 (dd, 3J = 4.9 Hz, 3J = 
3.7 Hz, 1H, H-2), 4.08 (ddd, 3J = 9.9 Hz, 3J = 6.6 Hz, 3J = 3.5 Hz, 1H, H-4), 3.88 (dd, 2J = 10.6 Hz, 3J = 3.5 Hz, 1H, Ha-5), 3.86 (d, 3J = 6.2 Hz, 2H, 
CH2OH), 3.66 (dd, 2J = 10.6 Hz, 3J = 6.6 Hz, 1H, Hb-5), 3.06 (s, 1H, OH), 2.19-2.09 (m, 1H, H-3), 1.52 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 0.90 (s, 
9H, SiC(CH3)3), 0.091 (s, 3H, Si(CH3)2), 0.087 (s, 3H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 112.2 (C(CH3)2), 105.0 (C-1), 82.6 
(C-2), 80.7 (C-4), 64.0 (C-5), 59.6 (CH2OH), 50.0 (C-3), 26.9 (C(CH3)2), 26.4 (C(CH3)2), 26.0 (SiC(CH3)3), 18.4 (SiC(CH3)3), -5.32 (Si(CH3)2) ppm. ESI-
HRMS calcd. for [C15H30O5Si + NH4]+: 336.2201,  found: 336.2204. 
 
5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-formyl-1,2-O-isopropylidene-α-D-ribofuranose (9): The title compound was prepared according to a 
modified procedure of Parr et al.[41] To a solution of oxalyl chloride (6.91 mL, 10.1 g, 79.6 mmol, 1.10 eq.) in dry DCM (380 mL) was slowly added DMSO 
(11.3 mL, 12.4 g, 159 mmol, 2.20 eq.) under N2 at -78 °C. The temperature was maintained below -60 °C and evolving gas was purged. After the mixture 
was stirred for 1 h at -60 °C, a solution of alcohol 9a (23.0 g, 72.2 mmol, 1.00 eq.) in dry DCM (70 mL) was added to the reaction mixture over 5 min and 
stirred for 2 h. Triethylamine (30.2 mL, 21.9 g, 217 mmol, 3.00 eq.) was added and the suspension was stirred for a further hour at -60 °C. The reaction 
mixture was warmed to RT, quenched with saturated aqueous NaHCO3 (150 mL) and extracted with DCM (3x150 mL). The combined organic layers 
were dried over anhydrous MgSO4, filtered and volatile components removed under reduced pressure. Purification of the crude product was performed 
by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:14:1) to give aldehyde 9 (21.2 g 67.0 mmol, 93%) as a colorless oil. It was also 
possible to use the crude product in the next step without further purification. Rf = 0.61 (isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2931, 1726, 1472, 1382, 
1253, 1100, 1019, 778 cm-1. 1H NMR, COSY (400 MHz, CDCl3): δ = 9.78 (d, 4J = 1.2 Hz, 1H, CHO), 5.87 (d, 3J = 3.7 Hz, 1H, H-1), 5.03 (dd, 3J = 5.2 Hz, 
3J = 3.7 Hz, 1H, H-2), 4.55 (ddd, 3J = 9.5 Hz, 3J = 3.6 Hz, 3J = 3.2 Hz, 1H, H-4), 3.86 (dd, 2J = 11.3 Hz, 3J = 3.6 Hz, 1H, Ha-5), 3.78 (dd, 2J = 11.3 Hz, 3J 
= 3.2 Hz, 1H, Hb-5), 3.02 (dd, 3J = 9.5 Hz, 3J = 5.2 Hz, 4J = 1.2 Hz, 1H, H-3), 1.48 (s, 3H, C(CH3)2), 1.33 (s, 3H, C(CH3)2), 0.86 (s, 9H, SiC(CH3)3), 0.04 
(s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 198.0 (CHO), 113.1 (C(CH3)2), 105.7 (C-1), 80.8 (C-2), 
  
 
78.2 (C-4), 62.8 (C-5), 56.6 (C-3), 26.8 (C(CH3)2), 26.6 (C(CH3)2), 26.0 (SiC(CH3)3), 18.5 (SiC(CH3)3), 5.31 (Si(CH3)2), -5.31 (Si(CH3)2) ppm. EI-HRMS 
calcd. for [C15H28O5Si - CH3]+: 301.1466, found: 301.1475. 
 
5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-(2,2-dibromovinyl)-1,2-O-isopropylidene-α-D-ribofuranose (10a): The title compound was prepared 
according to a modified procedure of Betkekar et al.[39] A solution of tetrabromomethane (43.0 g, 130 mmol, 2.00 eq.) in DCM (350 mL) was mixed with 
triphenylphosphine (68.0, 259 mmol, 4.00 eq.) under N2 at 0 °C and stirred for 1 h at this temperature. The resulting orange solution was treated with a 
solution of aldehyde 9 (20.5 g, 64.8 mmol, 1.00 eq.) in DCM (120 mL). The dark suspension was stirred at RT for 12 h. After removal of volatile materials, 
the crude product was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:14:1) to provide dibromo compound 10a (26.1 g, 
55.3 mmol, 85%) as a slightly yellow oil. Rf = 0.83 (isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2929, 1471, 1382, 1252, 1097, 1020, 777 cm-1. 1H NMR, 
COSY (400 MHz, CDCl3): δ = 6.49 (d, 3J = 9.4 Hz, 1H, Br2CCH), 5.82 (d, 3J = 3.5 Hz, 1H, H-1), 4.68 (dd, 3J = 4.5 Hz, 3J = 3.5 Hz, 1H, H-2), 4.03 (ddd, 
3J = 9.9 Hz, 3J = 3.6 Hz, 3J = 3.4 Hz, 1H, H-4), 3.81 (dd, 2J = 11.5 Hz, 3J = 3.4 Hz, 1H, Ha-5), 3.66 (dd, 2J = 11.5 Hz, 3J = 3.6 Hz, 1H, Hb-5), 3.00 (td, 3J = 
9.9 Hz, 3J = 4.5 Hz, 1H, H-3), 1.53 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 0.89 (s, 9H, SiC(CH3)3), 0.06 (s, 6H, Si(CH3)2) ppm. 13C NMR, HSQC, HMBC 
(101 MHz, CDCl3): δ = 133.2 (Br2CCH), 112.2 (C(CH3)2), 105.2 (C-1), 91.8 (Br2CCH), 81.7 (C-2), 80.9 (C-4), 62.3 (C-5), 49.2 (C-3), 26.9 (C(CH3)2), 26.4 
(C(CH3)2), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 5.16 (Si(CH3)2), -5.22 (Si(CH3)2) ppm. EI-HRMS calcd. for [C16H28 Br2O4Si - CH3]+: 454.9884, found: 
454.9882 
 
5-O-(tert-Butyldimethylsilyl)-3-deoxy-3-ethynyl-1,2-O-isopropylidene-α-D-ribofuranose (10b): The title compound was prepared according to a 
modified procedure of Betkekar et al.[39] Dibromo compound 10a (25.0 g, 52.9 mmol, 1.00 eq.) was dissolved in dry THF (270 mL) and cooled to -78 °C 
under N2. n-Butyl lithium (48.7 mL, 122 mmol, 2.5M in hexanes, 2.30 eq.) was added dropwise over a period of 10 min until a red solution was formed. 
After stirring for 1.5 h at this temperature, the reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) and extracted with EtOAc 
(3 x 200 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification of the residue was 
conducted by flash-column chromatography (silica gel, isohexane/EtOAc, 9:14:1) to afford ethynyl compound 10b (13.7 g 43.8 mmol, 83%) as a 
yellowish oil. Rf = 0.60 (isohexanes/EtOAc, 4:1). IR (ATR): ṽ = 3279, 2930, 1472, 1373, 1252, 1215, 1110, 1017, 815, 777 cm−1. 1H NMR, COSY (400 MHz, 
CDCl3): δ = 5.81 (d, 3J = 3.6 Hz, 1H, H-1), 4.72 (dd, 3J = 4.1 Hz, 3J = 3.6 Hz, 1H, H-2), 4.11 (ddd, 3J = 10.1 Hz, 3J = 2.9 Hz, 3J = 2.0 Hz, 1H, H-4), 3.97 
(dd, 2J = 12.0, 3J = 2.0 Hz, 1H, Ha-5), 3.79 (dd, 2J = 12.0, 3J = 2.9 Hz, 1H, Hb-5), 2.97 (ddd, 3J = 10.1 Hz, 3J = 4.1 Hz, 4J = 2.6 Hz, 1H, H-3), 2.21 (d, 4J = 
2.6 Hz, 1H, CCH), 1.57 (s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2), 0.89 (s, 9H, SiC(CH3)3), 0.08 (s, 3H, Si(CH3)2), 0.07 (s, 3H, Si(CH3)2) ppm. 13C NMR, 
HSQC, HMBC (101 MHz, CDCl3): δ = 112.3 (C(CH3)2), 105.1 (C-1), 81.9 (C-4), 81.2 (C-2), 78.2 (CCH), 72.3 (CCH) , 61.1 (C-5), 36.3 (C-3), 26.8 (C(CH3)2), 
26.5 (C(CH3)2), 26.1 (SiC(CH3)3), 18.6 (SiC(CH3)3), -5.1 (Si(CH3)2), -5.2 (Si(CH3)2) ppm. ESI-HRMS calcd. for [C16H28O4Si + NH4]+: 330.2095, found: 
330.2098. 
 
3-Deoxy-3-ethynyl-1,2-O-isopropylidene-α-D-ribofuranose (10c): The title compound was prepared according to a modified procedure of Betkekar et 
al.[39] To a yellow solution of ethynyl compound 10b (13.3 g, 42.6 mmol, 1.00 eq.) in THF (200 mL) was added TBAF (55.3 mL, 55.3 mmol, 1M in THF, 
1.30 eq.) at RT. The resulting dark solution was stirred for 4 h at this temperature. The reaction mixture was quenched with silica and the solvent was 
concentrated under reduced pressure. The crude product was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 2:11:12:3) to 
yield alcohol 10c (8.03 g, 40.5 mmol, 95%) as colorless crystals. M.p. = 43 – 45 °C. Rf = 0.38 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 3456, 3279, 2936, 
1375, 1249, 1215, 1105, 1007, 871 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 5.83 (d, 3J = 3.5 Hz, 1H, H-1), 4.75 (dd, 3J = 4.1 Hz, 3J = 3.5 Hz, 1H, 
H-2), 4.17 (ddd, 3J = 10.3 Hz, 3J = 3.2 Hz, 3J = 3.0 Hz, 1H, H-4), (4.00 (dd, 2J = 12.2 Hz, 3J = 3.2 Hz, 1H, Ha-5), 3.71 (ddd, 2J = 12.2 Hz, 3J = 8.8 Hz, 3J 
= 3.0 Hz, 1H, Hb-5), 2.96 (ddd, 3J = 10.3 Hz, 3J = 4.1 Hz, 4J = 2.5 Hz, 1H, H-3), 2.23 (d, 4J = 2.5 Hz, 1H, CCH), 1.84 (dd, 3J = 8.8 Hz, 4.2 Hz, 1H, OH), 
1.58 (s, 3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 112.7 (C(CH3)2), 105.1 (C-1), 81.4 (C-4), 81.3 (C-2), 
77.6 (CCH), 72.6 (CCH), 60.6 (C-5), 36.3 (C-3), 26.7 (C(CH3)2), 26.5 (C(CH3)2) ppm. EI-HRMS calcd. for [C10H14O4 - CH3]+: 183.0652, found: 183.0652. 
3-Deoxy-3-ethynyl-1,2-O-isopropylidene-5-O-tosyl-α-D-ribofuranose (10d): p-Toluenesulfonyl chloride (15.5 g, 56.8 mmol, 1.50 eq.) was dissolved 
in dry pyridine (50.0 mL) and added to a solution of alcohol 10c (7.5 g 37.8 mmol, 1.00 eq.) in pyridine (150 mL) at 0 °C. The reaction mixture was stirred 
for 18 h at RT and finally quenched with MeOH (10 mL). After removal of volatile components, purification of the residue by flash-column chromatography 
(silica gel isohexanes/EtOAc, 2:11:1) gave tosyl compound 10d (11.7 g, 33.2 mmol, 87%) as colorless crystals. Crystallization from isohexanes/EtOAc 
(vapor diffusion) provided suitable single crystals for X-ray characterization. M.p. = 113 – 114 °C. Rf = 0.73 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 
3296, 2990, 1598, 1450, 1360, 1176, 1097, 958, 813 665 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 7.80 (d, 3J = 8.2 Hz, 2H, aryl-CH-CSO3), 7.34 (d, 
3J = 8.2 Hz, 2H, aryl-CH-CCH3), 5.72 (d, 3J = 3.5 Hz, 1H, H-1), 4.68 (dd, 3J = 4.0 Hz, 3J = 3.5 Hz, 1H, H-2),, 4.40 – 4.31 (m, 1H, Ha-5), 4.22 – 4.14 (m, 
2H, H-4, Hb-5), 2.84 (ddd, 3J = 9.7 Hz, 3J = 4.0 Hz, 4J = 2.4 Hz, 1H, H-3), 2.44 (s, 3H, aryl-CH3), 2.21 (d, 4J = 2.4 Hz, 1H, CCH), 1.52 (s, 3H, C(CH3)2), 
1.34 (s, 3H, C(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 145.1 (aryl-C-SO3), 132.7 (aryl-C-CH3), 130.0 (aryl-CH-CCH3), 128.2 (aryl-
CH-CSO3), 112.8 (C(CH3)2), 105.0 (C-1), 80.7 (C-2), 78.5 (C-4), 76.5 (CCH), 73.3 (CCH), 67.4 (C-5), 37.0 (C-3), 26.7 (C(CH3)2), 26.4 (C(CH3)2), 21.8 
(aryl-CH3) ppm. ESI-HRMS calcd. for [C17H20O6S + H]-: 353.1054, found: 353.1057. ESI-HRMS calcd. for [C17H20O6S + NH4]+: 370.1319, found: 370.1317. 
 
5-Azido-3,5-dideoxy-3-ethynyl-1,2-O-isopropylidene-α-D-ribofuranose (10): A mixture of tosyl compound 10d (10.5 g, 29.8 mmol, 1.00 eq.) and 
sodium azide (8.86 g, 95.3 mmol, 3.20 eq.) was suspended in DMF (300 mL) and stirred under N2 at 80 °C for 3 h. The yellow suspension was diluted 
with brine (200 mL) and extracted with EtOAc (4 x 300 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated 
in vacuo. Purification of the crude product by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:14:1) yielded azide compound 10 (6.25 g, 
28.0 mmol, 94%) as a colorless oil. Rf = 0.67 (isohexanes/EtOAc = 2:1). IR (ATR): ṽ = 3280, 2989, 2100, 1375, 1216, 1166, 1105, 1012, 871 cm−1. 1H 
NMR, COSY (400 MHz, CDCl3): δ = 5.86 (d, 3J = 3.6 Hz, 1H, H-1), 4.75 (dd, 3J = 4.1 Hz, 3J = 3.6 Hz, 1H, H-2), 4.24 (ddd, 3J = 10.2 Hz, 3J = 3.9 Hz, 3J = 
2.7 Hz, 1H, H-4), 3.76 (dd, 2J = 13.6 Hz, 3J = 2.7 Hz, 1H, Ha-5), 3.37 (dd, 2J = 13.6 Hz, 3J = 3.9 Hz, 1H, Hb-5), 2.88 (ddd, 3J = 10.2 Hz, 3J = 4.1 Hz, 4J = 
2.5 Hz, 1H, H-3), 2.25 (d, 4J = 2.5 Hz, 1H, CCH), 1.57 (s, 3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 112.8 
(C(CH3)2), 105.1 (C-1), 81.0 (C-2), 79.7 (C-4), 76.9 (CCH), 73.2 (CCH), 50.7 (C-5), 37.9 (C-3), 26.7 (C(CH3)2), 26.4 (C(CH3)2) ppm. EI-HRMS calcd. for 
[C10H13N3O3 - CH3]+: 208.0717, found: 208.0717. 
 
1,2-di-O-Acetyl-5-azido-3,5-dideoxy-3-ethynyl-D-ribofuranose (11): A stirred solution of azide compound 10 (6.00 g, 26.9 mmol, 1.00 eq.) in acetic 
acid (100 mL) and acetic anhydride (50 mL) was treated with concentrated sulfuric acid (96%, 1.30 mL) at 0 °C. The reaction mixture turned dark and 
was stirred for 5 h at RT. After careful quenching with saturated aqueous NaHCO3 solution (200 mL) and solid NaHCO3 until CO2 evolution stopped, the 
reaction was extracted with DCM (4 x 200 mL). The organic phase was washed with brine (200 mL), dried over anhydrous MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 9:1) to afford diacetate compound 
11 (5.61 g, 21.0 mmol, 78%) as colorless crystals. α/β = 1:6. β anomer could be isolated for analysis. Crystallization from isohexanes/EtOAc (vapor 
  
 
diffusion) provided suitable single crystals of the β anomer for X-ray characterization. M.p. = 81 – 82 °C. Rf (α anomer) = 0.55 (isohexanes/EtOAc = 4:1). 
Rf (β anomer) = 0.46 (isohexanes/EtOAc, 4:1). IR (ATR, β anomer): ṽ = 3281, 2934, 2099, 1743, 1438, 1371, 1205, 1097, 1024, 959, cm−1. Major β 
anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 6.12 (s, 1H, H-1), 5.37 (d, 3J = 4.5 Hz, 1H, H-2), 4.38 (ddd, 3J = 10.0 Hz, 3J = 3.2 Hz, 3J = 3.0 Hz, 1H, 
H-4), 3.75 (dd, 2J = 13.7 Hz, 3J = 3.0 Hz, 1H, Ha-5), 3.39 (ddd, 3J = 10.0 Hz, 3J = 4.5 Hz, 4J = 2.5 Hz, 1H, H-3), 3.24 (dd, 2J = 13.7 Hz, 3J = 3.2 Hz, 1H, 
Hb-5), 2.16 (d, 4J = 2.5 Hz, 1H, CCH), 2.14 (s, 3H, C-2-OCOCH3), 2.08 (s, 3H, C-1-OCOCH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 169.5 
(C-2-OCOCH3), 169.2 (C-1-OCOCH3), 98.7 (C-1), 83.7 (C-4), 76.8 (C-2), 76.0 (CCH), 73.6 (CCH), 51.0 (C-5), 34.5 (C-3), 21.12 (C-1-OCOCH3), 20.73 
(C-2-OCOCH3) ppm. ESI-HRMS calcd. for [C11H13N3O5 + H]+: 268.0928, found: 268.0930. ESI-HRMS calcd. for [C11H13N3O5 + NH4]+: 285.1193, found: 
285.1196. 
 
6-Benzoylamino-9-(2-O-acetyl-5-azido-3,5-dideoxy-3-ethynyl-β-D-ribofuranosyl)-9H-purine (12): N,O-Bis(trimethylsilyl)acetamid (BSA) (3.66 mL, 
3.05 g, 15.0 mmol, 4.00 eq.) was added under N2 to a stirred suspension of diacetate compound 11 (1.00 g, 3.74 mmol, 1.00 eq.) and 6-N-
benzoyladenine (1.79 g, 7.48 mmol, 2.00 eq.) in dichloroethane (40 mL) and heated to 80 °C for 1 h until a clear solution was obtained. The reaction 
mixture was brought to RT and treated with trimethylsilyl triflate (TMSOTf) (1.36 mL, 1.66 g, 7.48 mmol, 2.00 eq.). The dark red solution was stirred at 
80 °C for 4 h and additional 8 h at RT. The reaction was quenched with saturated aqueous NaHCO3 (30 mL) and extracted with DCM (4 x 50 mL). The 
combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue was purified by flash-column 
chromatography (silica gel, isohexanes/EtOAc, 2:11:11:2EtOAc) to provide nucleoside 12 (1.02 g, 2.29 mmol, 61%) as a colorless foam. The 
reaction could also be performed on a 4 g scale of the diacetate starting material 11 (yield: 50%). M.p. = 110 °C (decomp.). Rf = 0.20 (isohexanes/EtOAc 
= 1:2). Rf = 0.24 (DCM/MeOH, 100:5). IR (ATR): ṽ = 3296, 3060, 2932, 2103, 1747, 1698, 1581, 1218, 1072, 797 cm−1. 1H NMR, COSY (400 MHz, 
CDCl3): δ = 9.27 (s, 1H, NH), 8.74 (s, 1H, H-2), 8.16 (s, 1H, H-8), 7.98 (d, 3J = 7.7 Hz, 2H, aryl-o-CH), 7.58 – 7.53 (m, 1H, aryl-p-CH), 7.46 (t, 3J = 7.7 
Hz, 2H, aryl-m-CH), 6.09 (s, 1H, H-1’), 5.87 (d, 3J = 5.7 Hz, 1H, H-2’), 4.38 (ddd, 3J = 10.0 Hz, 3J = 4.8 Hz, 4J = 2.7 Hz, 1H, H-4’), 4.07 (ddd, 3J = 10.0 
Hz, 3J = 5.7 Hz, 4J = 2.4 Hz, 1H, H-3’), 3.79 (dd, 2J = 13.6 Hz, 3J = 2.7 Hz, 1H, Ha-5’), 3.57 (dd, 2J = 13.6 Hz, 3J = 4.8 Hz, 1H, Hb-5’), 2.26 (d, 4J = 2.4 Hz, 
1H, CCH), 2.18 (s, 3H, CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 169.6 (OCOCH3), 164.8 (N-CO-aryl), 152.8 (C-2), 151.2 (C-4), 149.9 
(C-6), 142.0 (C-8), 133.6 (aryl-C-CO-N), 132.9 (aryl-p-CH), 128.9 (aryl-m-CH), 128.0 (aryl-o-CH), 123.7 (C-5), 89.7 (C-1’), 83.0 (C-4’), 76.9 (C-2’), 75.7 
(CCH), 74.4 (CCH), 51.2 (C-5’), 36.2 (C-3’), 20.7 (OCOCH3) ppm. ESI-HRMS calcd. for [C21H18N8O4 + H]+: 447.1524, found: 447.1529. 
 
6-Benzoylamino-9-(2-O-acetyl-5-amino-3,5-dideoxy-3-ethynyl-β-D-ribofuranosyl)-9H-purine (5a): Trimethylphosphine (4.48 mL, 4.48 mmol, 1.0M in 
THF, 2.00 eq.) was added to a stirred solution of nucleoside 12 (1.00 g, 2.24 mmol, 1.00 eq.) in THF (25 mL). After 5 min the reaction mixture turned 
turbid under N2 evolution and was heated to 40 °C for 1.5 h. The reaction mixture was treated with water (0.44 mL, 24.6 mmol, 11.0 eq.) and stirred for 
10 h at RT. Volatile materials were removed under reduced pressure and the residue was purified by flash-column chromatography (silica gel, 
DCM/MeOH, 100:2100:5) to give amino compound 5a (0.62 g, 1.48 mmol, 66%) as a colorless foam. The reaction could also be performed on a 4 g 
scale of the azide starting material 12 (yield: 56%). Rf = 0.34 (DCM/MeOH = 5:1). IR (ATR): ṽ = 3366, 3275, 2918, 1747, 1640, 1422, 1296, 1138, 943, 
860 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 8.75 (s, 1H, H-2), 8.27 (s, 1H, H-8), 8.00 (d, 3J = 7.7 Hz, 2H, aryl-o-CH), 7.61 – 7.55 (m, 1H, aryl-p-
CH), 7.49 (t, 3J = 7.7 Hz, 2H, aryl-m-CH), 6.08 (s, 1H, H-1’), 5.81 (d, 3J = 5.9 Hz, 1H, H-2’), 4.27 (ddd, 3J = 9.9 Hz, 3J = 4.8 Hz, 4J = 3.0 Hz, 1H, H-4’), 
4.02 (ddd, 3J = 9.9 Hz, 3J = 5.9 Hz, 4J = 2.4 Hz, 1H, H-3’), 3.24 (dd, 2J = 14.0 Hz, 3J = 3.0 Hz, 1H, Ha-5’), 3.01 (dd, 2J = 14.0 Hz, 3J = 4.8 Hz, 1H, Hb-5’), 
2.23 (d, 4J = 2.4 Hz, 1H, CCH), 2.19 (s, 3H, CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 169.8 (OCOCH3), 164.9 (N-CO-aryl), 152.8 (C-
2), 151.3 (C-4), 149.9 (C-6), 142.2 (C-8), 133.6 (aryl-C-CO-N), 132.9 (aryl-p-CH), 128.9 (aryl-m-CH), 128.0 (aryl-o-CH), 123.7 (C-5), 89.5 (C-1’), 85.4 (C-
4’), 77.4 (C-2’), 76.7 (CCH), 73.9 (CCH), 42.6 (C-5’), 35.8 (C-3’), 20.9 (OCOCH3) ppm. ESI-HRMS calcd. for [C21H20N6O4 + H]+: 421.1619, found: 
421.1623. 
 
6-Benzoylamino-9-(2-O-acetyl-5-(tert-butoxycarbonyl)amino-3,5-dideoxy-3-ethynyl-β-D-ribofuranosyl)-9H-purine (5): A mixture of amine 
compound 5a (2.00 g, 4.76 mmol, 1.00 eq.), triethylamine (1.99 mL, 1.44 g, 14.3 mmol, 3.00 eq.) and di-tert-butyldicarbonate (1.53 mL, 1.56 g, 
7.14 mmol, 1.50 eq.) in dry DCM (40 mL) was stirred at RT for 16 h. MeOH (3 mL) was added and volatile materials were removed in vacuo. The residue 
was purified by flash-column chromatography (silica gel, DCM/MeOH, 100:2100:3) to give the title compound 5 as a colorless foam (1.59 g, 3.05 mmol, 
64%). M.p. = 143 °C (decomp.). Rf = 0.20 (DCM/MeOH = 100:5). IR (ATR): ṽ = 3265, 2977, 1749, 1699, 1610, 1516, 1455, 1248, 1227, 1086 cm−1. 1H 
NMR, COSY (400 MHz, CDCl3): δ = 9.15 (s, 1H, NHBz), 8.79 (s, 1H, H-2), 8.03 (s, 1H, H-8), 8.01 (d, 3J = 7.7 Hz, 2H, aryl-o-CH), 7.63 – 7.56 (m, 1H, 
aryl-p-CH), 7.49 (t, 3J = 7.7 Hz, 2H, aryl-m-CH), 6.26 (dd, 3J = 7.0 Hz, 4J = 3.7 Hz, 1H, NHBoc), 5.99 (d, 3J = 2.4 Hz, 1H, H-1’), 5.66 (dd, 3J = 6.6 Hz, 3J 
= 2.4 Hz, 1H, H-2’), 4.43 (ddd, 3J = 9.4 Hz, 3J = 3.7 Hz, 3J = 3.2 Hz, 1H, H-4’), 4.03 (ddd, 3J = 9.4 Hz, 3J = 6.6 Hz, 4J = 2.4 Hz, 1H, H-3’), 3.67 (ddd, 2J = 
14.5 Hz, 3J = 7.0 Hz, 3J = 3.7 Hz, 1H, Ha-5’), 3.57 (ddd, 2J = 14.5 Hz, 3J = 7.0 Hz, 3J = 3.2 Hz, 1H, Hb-5’), 2.28 (d, 4J = 2.4 Hz, 1H, CCH), 2.18 (s, 3H, 
OCOCH3), 1.46 (s, 9H, C(CH3)3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 170.0 (OCOCH3), 164.7 (N-CO-aryl), 156.5 (N-CO-O), 152.9 (C-
2), 151.1 (C-4), 150.2 (C-6), 142.4 (C-8), 133.5 (aryl-C-CO-N), 133.0 (aryl-p-CH), 129.0 (aryl-m-CH), 128.1 (aryl-o-CH), 124.2 (C-5), 90.5 (C-1’), 83.5 (C-
4’), 79.6 (C(CH3)3), 77.4 (C-2’), 76.4 (CCH), 74.4 (CCH), 41.6 (C-5’), 35.8 (C-3’), 28.6 (C(CH3)3), 20.8 (OCOCH3) ppm. ESI-HRMS calcd. for [C26H28N6O6 
+ H]+: 521.2143, found: 521.2150. 
 
Benzyl 3,4-O-isopropylidene-β-D-arabinopyranoside (14): The title compound was prepared according to a modified procedure of Shing et al.[42] 
Benzyl β-D-arabinopyranoside (48.0 g, 200 mmol, 1.00 eq.) was suspended in acetone (500 mL) and 2,2-dimethoxypropane (49.0 mL, 41.6 g; 400 mmol, 
2.00 eq.). After addition of p-toluenesulfonic acid monohydrate (1.14 g, 5.99 mmol, 0.03 eq.), the reaction mixture was stirred at 60 °C for 2 h to obtain a 
clear solution. The reaction was neutralized by treatment with triethylamine (0.84 mL, 0,61 g, 5.99 mmol, 1.00 eq.). Volatile components were removed 
in vacuo and the residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 2:13:21:1, gradient elution) to furnish the title 
compound 14 (46.8 g, 167 mmol, 84%) as a colorless oil. Rf = 0.54 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 3221, 2938, 1499, 1453, 1315, 1252, 1048, 
1001, 848, 783, 701 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 7.42 – 7.28 (m, 5H, aryl-H), 4.94 (d, 3J = 3.6 Hz, 1H, H-1), 4.79 (d, 2J = 11.7 Hz, 1H, 
PhCH2O), 4.55 (d, 2J = 11.7 Hz, 1H, PhCH2O), 4.24 (ddd, 3J = 6.2 Hz, 3J = 2.6 Hz, 3J = 1.2 Hz, 1H, H-4), 4.21 (q, 3J = 6.2 Hz, 1H, H-3), 4.01 (dd, 2J = 
13.2 Hz, 3J = 2.6 Hz, 1H, Ha-5), 3.93 (dd, 2J = 13.2 Hz, 3J = 1.2 Hz, 1H, Hb-5), 3.80 (dd, 3J = 6.2 Hz, 3.6 Hz, 1H, H-2), 2.22 (br s, 1H, OH), 1.53 (s, 3H, 
CH3), 1.36 (s, 3H, CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 137.1 (aryl-C-CH2), 128.7 (aryl-m-CH), 128.22 (aryl-p-CH), 128.15 (aryl-
o-CH), 109.4 (C(CH3)2), 97.0 (C-1), 76.1 (C-4), 73.1 (C-3), 70.1 (C-2), 69.9 (PhCH2O), 59.9 (C-5), 28.0 (CH3), 26.1 (CH3) ppm. ESI-HRMS calcd. for 
[C15H20O5 + NH4]+: 298.1649, found: 298.1651. EI-HRMS calcd. for [C15H20O5 - CH3]+: 265.1071, found: 265.1084. 
 
Benzyl 2-deoxy-2-C-[(ethoxycarbonyl)methylene]-3,4-O-isopropylidene-β-D-arabinofuranoside (15): The title compound was prepared according 
to a modified procedure of Kaiya et al.[43] Oxalyl chloride (15.3 mL, 22.4 g, 176 mmol, 1.15 eq.) was dissolved in dry DCM (600 mL). After cooling to 
−78 °C, dry DMSO (25.1 mL, 27.6 g, 352 mmol, 2.30 eq.) was added dropwise and the mixture was stirred at −60 °C for 1 h until no further gas 
  
 
development was observed. Subsequently, a solution of acetonide compound 14 (43.0 g, 153 mmol, 1.00 eq.) in dry DCM (150 mL) was added slowly 
over 10 min and the mixture was stirred at -60 °C for 2 h. The reaction mixture was treated with triethylamine (64.1 mL, 46.6 g, 460 mmol, 3.00 eq.), 
stirred at -60 °C for 1 h, quenched upon addition of saturated aqueous NaHCO3 (300 mL) and extracted with DCM (3 x 300 mL). The combined organic 
layers were washed with brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. Ketone 15a was obtained as a waxy 
syrup which was used in the next step without further purification. EI-HRMS calcd. for [C15H18O5 - CH3]+: 263.0914, found: 263.0914. 
A mixture of crude ketone 15a (42.0 g, 151 mmol, 1.00 eq.) and (carbethoxymethylene)triphenylphosphorane[44] (68.3 g, 196 mmol, 1.30 eq.) in DCM 
(400 mL) was stirred at RT for 12 h. Volatile components were evaporated and the residue was purified by flash-column chromatography (silica gel, 
isohexanes/EtOAc, 4:1) to afford the title compound 15 as a colorless oil (46.0 g, 132 mmol, 86% over 2 steps). E/Z = 4:1 (inseparable mixture by fcc). 
Rf = 0.84 (isohexanes/EtOAc = 2:1). IR (ATR, E/Z-mixture): ṽ = 2983, 1718, 1372, 1214, 1150, 1020, 853, 736, 699 cm−1. Major E-Isomer: 1H NMR, 
COSY (400 MHz, CDCl3): δ = 7.41 – 7.32 (m, 5H, aryl-H), 6.41 (d, 4J = 1.8 Hz, 1H, C=CH), 6.06 (d, 3J = 7.5 Hz, 1H, H-3), 5.44 (d, 4J = 1.8 Hz, 1H, H-1), 
4.86 (d, 2J = 11.9 Hz, 1H, OCH2Ph), 4.62 (d, 2J = 11.9 Hz, 1H, OCH2Ph), 4.34 (dd, 3J = 7.5 Hz, 3J = 1.7 Hz, 1H, H-4), 4.20 (q, 3J = 7.1 Hz, 2H, OCH2CH3), 
3.70 (d, 3J = 1.7 Hz, 2H, H-5), 1.53 (s, 3H, C(CH3)2), 1.40 (s, 3H, C(CH3)2), 1.30 (t, 3J = 7.1 Hz, 3H, OCH2CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, 
CDCl3): δ = 165.5 (C=O), 147.9 (C-2), 137.6 (aryl-C-CH2), 128.6 (aryl-m-CH), 128.1 (aryl-p-CH), 128.0 (aryl-o-CH), 124.4 (C=CH), 110.6 (C(CH3)2), 95.8 
(C-1), 75.2 (C-4), 69.5 (PhCH2O), 68. 6 (C-3), 63.2 (C-5), 60.8 (OCH2CH3), 26.4 (C(CH3)2), 25.3 (C(CH3)2), 14.3 (OCH2CH3) ppm. ESI-HRMS calcd. for 
[C19H24O6 + NH4]+: 366.1911, found: 366.1911. 
 
Benzyl 2-deoxy-2-C-[(ethoxycarbonyl)methyl]-3,4-O-isopropylidene-β-D-ribopyranoside (16): The title compound was prepared according to a 
modified procedure of Kaiya et al.[43] Vinyl compound 15 (45.0 g, 129 mmol, 1.00 eq.) was dissolved in EtOH (300 mL) and Raney-Ni (ca. 15 mL) was 
added to the solution at RT. The reaction vessel was evacuated and flushed with hydrogen three times. Subsequently, the mixture was stirred under 
hydrogen atmosphere for 20 h. Upon completion of the reaction as monitored by TLC, the reaction mixture was filtered through celite. Volatile materials 
were removed in vacuo and the residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 4:1) to yield reduced compound 16 
(40.8 g, 116 mmol, 90%) as a colorless oil. dr = 13:1. Rf = 0.33 (isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2983, 1732, 1455, 1370, 1212, 1071, 1021, 870, 
738, 699 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 7.38 – 7.25 (m, 5H, aryl-H), 4.82 (d, 3J = 11.7 Hz, 1H, OCH2Ph), 4.64 (d, 3J = 8.0 Hz, 1H, H-1), 
4.49 (dd, 3J = 7.4 Hz, 3J = 2.8 Hz, 1H, H-3), 4.48 (d, 3J = 11.7 Hz, 1H, OCH2Ph), 4.24 (ddd, 3J = 7.4 Hz, 3J = 2.6 Hz, 3J = 2.3 Hz, 1H, H-4), 4.10 (q, 3J = 
7.2 Hz, 2H, OCH2CH3), 3.84 (dd, 2J = 12.8 Hz, 3J = 2.6 Hz, 1H, Ha-5), 3.63 (dd, 2J = 12.8 Hz, 3J = 2.3 Hz, 1H, Hb-5), 2.60 – 2.55 (m, 2H, CH2COO), 2.28 
(ddd, 3J = 8.0 Hz, 3J = 6.5 Hz, 3J = 2.8 Hz, 1H, H-2), 1.47 (s, 3H, C(CH3)2), 1.31 (s, 3H, C(CH3)2), 1.22 (t, 3J = 7.2 Hz, 3H, OCH2CH3) ppm. 13C NMR, 
HSQC, HMBC (101 MHz, CDCl3): δ = 172.2 (C=O), 138.1 (aryl-C-CH2), 128.5 (aryl-m-CH), 128.1 (aryl-p-CH), 127.8 (aryl-o-CH), 109.1 (C(CH3)2), 99.0 
(C-1), 73.2 (C-4), 72.6 (C-3), 69.7 (PhCH2O), 62.6 (C-5), 60.7 (OCH2CH3), 37.2 (C-2), 33.6 (CH2COO), 26.7 (C(CH3)2), 25.0 (C(CH3)2), 14.3 (OCH2CH3) 
ppm. EI-HRMS calcd. for [C19H26O6 - CH3]+:335.1489, found: 335.1481. 
 
2-Deoxy-3,4-O-isopropylidene-2-C-[(ethoxycarbonyl)methyl]-D-ribopyranose (17a): To a stirred solution of ester compound 16 (38.0 g, 108 mmol, 
1.00 eq.) in EtOH (250 mL) and THF (100 mL) was added Pd/C (10 wt.%, 1.70 g) under N2 at RT. The reaction vessel was evacuated and flushed with 
hydrogen three times. The mixture was stirred under hydrogen atmosphere for 24 h and then filtered through celite. The solution was concentrated to 
dryness under reduced pressure and the residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 4:11:1) to furnish 
anomeric alcohol 17a as a colorless oil (24.8 g, 95.3 mmol, 88%). α/β = 1:9 (inseparable mixture by fcc). Rf = 0.36 (isohexanes/EtOAc = 1:1). IR (ATR, 
α/β-mixture): ṽ = 2984, 1731, 1458, 1371, 1213, 1109, 1056, 1020, 868 cm-1. Major β anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 4.88 (dd, 3J = 8.3 
Hz, 3J = 4.8 Hz, 1H, H-1), 4.44 (dd, 3J = 7.1 Hz, 3J = 2.9 Hz, 1H, H-3), 4.23 (ddd, 3J = 7.1 Hz, 3J = 3.7 Hz, 3J = 3.4 Hz, 1H, H-4), 4.16 (q, 3J = 7.1 Hz, 2H, 
OCH2CH3), 3.88 (dd, 2J = 12.6 Hz, 3J = 3.4 Hz, 1H, Ha-5), 3.60 (dd, 2J = 12.6, 3J = 3.7 Hz, 1H, Hb-5), 3.26 (d, 3J = 4.8 Hz, 1H, OH), 2.66 (dd, 2J = 16.9 
Hz, 3J = 5.9 Hz, 1H, CH2COO), 2.59 (dd, 3J = 16.9 Hz, 2J = 8.3 Hz, 1H, CH2COO), 2.20 (ddd, 3J = 8.3 Hz, 3J = 5.9 Hz, 3J = 2.9 Hz, 1H, H-2), 1.45 (s, 3H, 
(CH3)2), 1.30 (s, 3H, C(CH3)2), 1.26 (t, J = 7.1 Hz, 3H, OCH2CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 172.8 (C=O), 109.2 (C(CH3)2), 
94.4 (C-1), 73.4 (C-3), 72.7 (C-4), 63.3 (C-5), 61.0 (OCH2CH3), 38.5 (C-2), 33.5 (CH2COO), 27.0 (C(CH3)2), 25.27 (C(CH3)2), 14.3 (OCH2CH3) ppm. EI-
HRMS calcd. for [C12H20O6 - CH3]+: 245.1020, found: 245.1023. 
 
Methyl 2-C-carboxymethyl-2-deoxy-2,3-lactone-D-ribofuranoside (17): The title compound was prepared according to a modified procedure of Li et 
al.[45] Anomeric alcohol 17a (20.7 g, 79.5 mmol, 1.00 eq.) was dissolved in AcOH/H2O (v/v 4:1, 400 mL) and stirred at RT for 24 h. Tthe mixture was 
heated to 40 °C for additional 2 h. Volatile materials were evaporated and the crude product 17b was co-evaporated with toluene (3 x 300 mL) and used 
in the next step without further purification. Rf = 0.05 (isohexanes/EtOAc = 1:1). EI-HRMS calcd. for [C12H20O6 - 2 x H2O]+: 184.0730, found: 184.0726. 
Concentrated sulfuric acid (0.56 mL) was added to a stirred solution of triol compound 17b in dry methanol (450 mL) at 0 °C. The reaction mixture was 
stirred at 4 °C for 72 h and then neutralized by addition of solid sodium bicarbonate. The resulting suspension was filtered through celite and the filtrate 
was concentrated to dryness under reduced pressure. Purification by flash-column chromatography (silica gel, isohexanes/EtOAc, 2:11:11:3) yielded 
lactone 17 (10.8 g, 57.4 mmol, 72% over 2 steps) as colorless crystals. α/β = 2:3. β anomer could be isolated for analysis. M.p. = 45 – 47 °C. Rf (α 
anomer) = 0.44 (DCM/MeOH = 100:5). Rf (β anomer) = 0.30 (DCM/MeOH = 100:5). IR (ATR, β anomer): ṽ = 3442, 2940, 1775, 1172, 1102, 1031, 1003, 
932 cm−1. Major β anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 5.16 (dd, 3J = 7.0 Hz, 3J = 0.9 Hz, 1H, H-3), 4.90 (d, 3J = 1.4 Hz, 1H, H-1), 4.49 – 
4.44 (m, 1H, H-4), 3.73 (dd, 2J = 12.8 Hz, 3J = 2.9 Hz, 1H, Ha-5), 3.68 (dd, 2J = 12.8, 3J = 3.6 Hz, 1H, Hb-5), 3.41 (s, 3H, OCH3), 3.13 – 3.05 (m, 1H, H-
2), 2.87 (dd, 2J = 18.6 Hz, 3J = 11.0 Hz,1H, CH2COO), 2.55 (dd, 2J = 18.6 Hz, 3J = 3.7 Hz, 1H, CH2COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, 
CDCl3): δ = 175.6 (C=O), 111.8 (C-1), 86.9 (C-4), 84.8 (C-3), 63.7 (C-5), 55.8 (OCH3), 46.6 (C-2), 32.4 (CH2COO) ppm. EI-HRMS calcd. for [C8H12O5 - 
CH2OH]+: 157.0495, found: 157.0494. 
 
Methyl 2-C-carboxymethyl-2,5-dideoxy-2,3-lactone-5-tosyl-D-ribofuranoside (18): To a stirred solution of lactone compound 17 (10.0 g, 53.1 mmol, 
1.00 eq.) in dry pyridine (300 mL) was added a solution of p-toluenesulfonyl chloride (13.2 g, 69.1 mmol, 1.30 eq.) in pyridine (40 mL) at 0 °C. After 
stirring at RT for 18 h, the reaction was quenched by treatment with MeOH (20 mL). Solvents were removed in vacuo and the residue was purified by 
flash-column chromatography (silica gel, hexane/EtOAc, 3:21:11:3) to give tosyl compound 18 as colorless crystals (13.9 g, 40.6 mmol, 76%). α/β = 
2:3 (inseparable mixture by fcc). Crystallization from isohexanes/EtOAc (vapor diffusion) provided suitable β single crystals for X-ray characterization. 
M.p. = 78 – 80 °C. Rf = 0.36 (isohexanes/EtOAc = 1:1). IR (ATR, α/β-mixture): ṽ = 2938, 1781, 1598, 1358, 1173, 1111, 979, 815, 665 cm−1. β anomer: 
1H NMR, COSY (400 MHz, CDCl3): δ = 7.82 – 7.75 (m, 2H, aryl H-2-2’), 7.40 – 7.32 (m, 2H, aryl H-3,-3’), 4.98 (dd, 3J = 7.0 Hz, 3J = 0.9 Hz, 1H, H-3), 
4.86 (d, 3J = 1.1 Hz, 1H, H-1), 4.41 – 4.34 (m, 1H, H-4), 4.10 (dd, 2J = 10.3 Hz, 3J = 7.6 Hz, 1H, Ha-5), 4.06 (dd, 2J = 10.3 Hz, 3J = 6.4 Hz, 1H, Hb-5), 3.24 
(s, 3H, OCH3), 3.13 – 3.05 (m, 1H, H-2), 2.82 (dd, 3J = 18.6 Hz, 3J = 11.0 Hz, 1H, CH2COO), 2.56 – 2.47 (m, 1H, CH2COO), 2.45 (s, 3H, aryl CH3) ppm. 
13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 175.3 (C=O), 145.5 (aryl C-4), 132.5 (aryl C-1), 130.13 (aryl C-3,-3’), 128.02 (aryl C-2,-2’), 111.6 (C-1), 
83.9 (C-3), 82.2 (C-4), 68.3 (C-5), 55.5 (OCH3), 45.5 (C-2), 31.6 (CH2COO), 21.8 (aryl CH3) ppm. α anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 7.82 
  
 
– 7.75 (m, 2H, aryl H-2-2’), 7.40 – 7.32 (m, 2H, aryl H-3-3’), 4.99 (d, 3J = 3.8 Hz, 1H, H-1), 4.82 (dd, 3J = 7.6 Hz, 3J = 2.7 Hz, 1H, H-3), 4.32 – 4.28 (m, 
1H, H-4), 4.23 (dd, 2J = 11.0 Hz, 3J = 3.1 Hz, 1H, Ha-5), 4.20 (dd, 2J = 11.0 Hz, 3J = 3.4 Hz, 1H, Hb-5), 3.31 (s, 3H, OCH3), 3.05 – 2.98 (m, 1H, H-2), 2.67 
(dd, 3J = 17.7 Hz, 3J = 1.5 Hz, 1H, CH2COO), 2.56 – 2.47 (m, 1H, CH2COO), 2.45 (s, 3H, aryl CH3) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ 
= 176.2 (C=O), 145.4 (aryl C-4), 132.4 (aryl C-1), 130.11 (aryl C-3,-3’), 128.03 (aryl C-2,-2’), 104.5 (C-1), 83.1 (C-3), 80.2 (C-4), 69.0 (C-5), 55.4 (OCH3), 
44.1 (C-2), 29.0 (CH2COO), 21.8 (aryl CH3) ppm. ESI-HRMS calcd. for [C12H20O6 + NH4]+: 360.1111, found: 360.1109. 
 
Methyl 5-azido-2-C-carboxymethyl-2,5-dideoxy-2,3-lactone-D-ribofuranoside (19): A mixture of tosyl compound 18 (13.0 g, 38.0 mmol, 1.00 eq.) 
and sodium azide (14.1 g, 152 mmol, 4.00 eq.) was suspended in DMF (300 mL) and stirred under N2 at 80 °C for 3 h. The yellow suspension was diluted 
with brine (200 mL) and extracted with EtOAc (4x300 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 4:12:11:1) to afford azide 
compound 19 (6.08 g, 28.5 mmol, 75%) as a colorless oil. α/β = 2:3 (inseparable mixture by fcc). Rf = 0.46 (isohexanes/EtOAc = 1:1). IR (ATR, α/β-
mixture): ṽ = 2936, 2100, 1776, 1444, 1282, 1160, 1110, 1031, 920 cm-1. β anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 4.95 (dd, 3J = 7.3 Hz, 3J = 
1.3 Hz, 1H, H-3), 4.92 (d, 3J = 1.3 Hz, 1H, H-1), 4.41 – 4.36 (m, 1H, H-4), 3.53 (dd, 2J = 12.7 Hz, 3J = 7.2 Hz, 1H, Ha-5), 3.39 (s, 3H, OCH3), 3.38 (m, 1H, 
Hb-5), 3.18 – 3.11 (m, 1H, H-2), 2.86 (dd, 2J = 18.6 Hz, 3J = 10.9 Hz, 1H, CH2COO), 2.56 (dd, 2J = 18.6 Hz, 3J = 4.7 Hz, 1H, CH2COO) ppm. 13C NMR, 
HSQC, HMBC (101 MHz, CDCl3): δ = 175.3 (C=O), 111.9 (C-1), 84.7 (C-3), 84.0 (C-4), 55.7 (OCH3), 53.1 (C-5), 45.8 (C-2), 31.8 (CH2COO) ppm. α 
anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 5.11 (d, 3J = 5.2 Hz, 1H, H-1), 4.81 (dd, 3J = 7.8 Hz, 3J = 2.9 Hz, 1H, H-3), 4.37 – 4.33 (m, 1H, H-4), 
3.68 (dd, 2J =  13.2 Hz, 3J = 3.4 Hz, 1H, Ha-5), 3.43 (dd, 2J = 13.2 Hz, 3J = 3.8 Hz, 1H, Hb-5), 3.38 (s, 3H, OCH3), 3.12 – 3.05 (m, 1H, H-2), 2.73 (dd, 2J 
= 17.7 Hz, 3J = 1.6 Hz, 1H, CH2COO), 2.54 (dd, 2J = 17.7 Hz, 3J = 9.1 Hz, 1H, CH2COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 176.3 
(C=O), 104.4 (C-1), 83.8 (C-3), 81.6 (C-4), 55.3 (OCH3), 52.1 (C-5), 44.4 (C-2), 29.0 (CH2COO) ppm. ESI-HRMS calcd. for [C8H11N3O4 + NH4]+: 231.1088, 
found: 231.1088. 
 
Methyl 5-azido-3-O-benzyl-2,5-dideoxy-2-C-[(benzyloxycarbonyl)methylene]-D-ribofuranoside (20): The title compound was prepared according to 
a modified procedure of Webber et al.[46] Azide compound 19 (5.05 g, 23.7 mmol, 1.00 eq.) was mixed with KOH (10.6g, 190 mmol, 8.00 eq.) in THF 
(250 mL). The stirred suspension was treated with benzyl bromide (28.1 mL, 40.5 g, 237 mmol, 10.0 eq.) and refluxed for 5 h. After cooling to 0 °C, the 
reaction was diluted with water (250 mL) and extracted with EtOAc (3 x 300 mL). The combined organic layers were washed with brine (500 mL), dried 
over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash-column chromatography (silica gel, 
isohexanes/EtOAc, 9:14:12:1) to furnish benzylated compound 20 as a colorless oil (8.89 g, 21.6 mmol, 91%). α/β = 2:3. β anomer could be isolated 
for analysis. Rf (α anomer) = 0.57 (isohexanes/EtOAc = 4:1). Rf (β anomer) = 0.48 (isohexanes/EtOAc = 4:1). IR (ATR, β anomer): ṽ = 2931, 2100, 1733, 
1455, 1282, 1168, 1057, 910, 738, 698 cm−1. β anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 7.40 – 7.26 (m, 10H, aryl H), 5.11 (d, 2J = 12.3 Hz, 1H, 
COOCH2Ph), 5.06 (d, 2J = 12.3 Hz, 1H, COOCH2Ph), 4.82 (d, 3J = 2.3 Hz, 1H, H-1), 4.43 (s, 2H, OCH2Ph), 4.16 – 4.11 (m, 1H, H-3), 4.14 – 4.08 (m, 1H, 
H-4), 3.37 (s, 3H, OCH3), 3.32 (dd, 2J = 12.7 Hz, 3J = 6.2 Hz, 1H, Ha-5), 3.25 (dd, 2J = 12.7 Hz, 3J = 4.3 Hz, 1H, Hb-5), 2.86 – 2.79 (m, 1H, H-2), 2.74 (dd, 
2J = 16.5 Hz, 3J = 7.6 Hz, 1H, CH2COO), 2.43 (dd, 2J = 16.5 Hz, 3J = 7.4 Hz, 1H, CH2COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 172.2 
(C=O), 137.5 (OCH2Ph-C-1), 135.9 (COOCH2Ph-C-1), 128.7, 128.6, 128.41, 128.38, 128.08, 127.8 (aryl 10C), 109.4 (C-1), 81.4 (C-4), 80.3 (C-3), 72.6 
(OCH2Ph), 66.6 (COOCH2Ph), 55.8 (OCH3), 54.3 (C-5), 44.2 (C-2), 30.5 (CH2COO) ppm. ESI-HRMS calcd. for [C22H25N3O5 + NH4]+: 429.2132, found: 
429.2138. 
 
Acetyl 5-azido-3-O-benzyl-2,5-dideoxy-2-C-[(benzyloxycarbonyl)methylene]-D-ribofuranoside (21): To a solution of benzylated compound 20 
(8.02 g, 19.5 mmol, 1.00 eq.) in AcOH (70 mL) and Ac2O (70 mL), was added concentrated H2SO4 (0.20 mL) at 0 °C. The solution was warmed to RT 
and stirred for 3 h. After careful quenching with saturated NaHCO3 solution (150 mL) and solid NaHCO3 until CO2 evolution stopped, the reaction was 
extracted with DCM (4 x 200 mL), washed with brine (400 mL), dried over anhydrous MgSO4 and filtered. Volatile materials were removed in vacuo and 
the residue was co-evaporated with toluene (2 x 100 mL). The crude product was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 
9:14:12:1) to obtain acetylated compound 21 as a colorless oil (7.27 g, 16.5 mmol, 85%). α/β = 3:2 (inseparable mixture by fcc). Rf = 0.25 
(isohexanes/EtOAc = 4:1). IR (ATR): ṽ = 2101, 1733, 1455, 1366, 1230, 1170, 1007, 899, 738, 698 cm−1. β anomer: 1H NMR, COSY (400 MHz, CDCl3): 
δ = 7.26 (s, 10H, aryl H), 6.09 (d, J = 2.4 Hz, 1H, H-1), 5.09 (d, 2J = 12.2 Hz, 1H, COOCH2Ph), 5.04 (d, 2J = 12.2 Hz, 1H, COOCH2Ph), 4.45 (s, 2H, 
OCH2Ph), 4.28 – 4.24 (m, 1H, H-3), 4.16 (ddd, 3J = 9.6 Hz, 3J = 5.0 Hz, 3J = 4.6 Hz, 1H, H-4), 3.43 (dd, 2J = 13.2 Hz, 3J = 4.6 Hz, 1H, Ha-5), 3.23 (dd, 2J 
= 13.2 Hz, 3J = 5.0 Hz, 1H, Hb-5), 3.00 – 2.92 (m, 1H, H-2), 2.78 (dd, 2J = 16.9 Hz, 3J = 8.4 Hz, 1H, CH2COO), 2.61 (dd, 2J = 16.9 Hz, 3J = 7.1 Hz, 1H, 
CH2COO), 2.07 (s, 3H, CH3COO) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 171.8 (COOBn), 170.1 (COOCH3), 137.3 (OCH2Ph-C-1), 135.7 
(COOCH2Ph-C-1), 128.71, 128.64, 128.51, 128.47, 128.20, 127.84 (aryl 10C), 101.3 (C-1), 82.2 (C-4), 78.9 (C-3), 72.8 (OCH2Ph), 66.8 (COOCH2Ph), 
52.5 (C-5), 43.7 (C-2), 30.3 (CH2COO), 21.3 (CH3COO) ppm. α anomer: 1H NMR, COSY (400 MHz, CDCl3): δ = 7.41 – 7.22 (m, 10H, aryl H), 6.36 (d, 3J 
= 4.8 Hz, 1H, H-1), 5.10 (s, 2H, COOCH2Ph), 4.46 (d, 2J = 12.0 Hz, 1H, OCH2Ph), 4.42 (d, 2J = 12.0 Hz, 1H, OCH2Ph), 4.32 – 4.27 (m, 1H, H-4), 4.01 
(dd, 3J = 7.0, 3J = 2.3 Hz, 1H, H-3), 3.35 (dd, 2J = 12.9 Hz, 3J = 5.1 Hz, 1H, Ha-5), 3.15 (dd, 2J = 12.9 Hz, 3J = 4.2 Hz, 1H, Hb-5), 2.89 – 2.82 (m, 1H, H-
2), 2.77 (dd, 2J = 16.7 Hz, 3J = 6.6 Hz, 1H, CH2COO), 2.61 (dd, 2J = 16.7 Hz, 3J = 5.8 Hz, 1H, CH2COO), 2.05 (s, 3H, CH3COO) ppm. 13C NMR, HSQC, 
HMBC (101 MHz, CDCl3): δ = 172.0 (COOBn), 170.5 (CH3COO), 137.8 (OCH2Ph-C-1), 135.8 (COOCH2Ph-C-1), 128.74, 128.59, 128.52, 128.51, 128.05, 
127.80 (aryl 10C), 98.2 (C-1), 84.4 (C-4), 79.2 (C-3), 72.6 (OCH2Ph), 66.7 (COOCH2Ph), 52.7 (C-5), 43.1 (C-2), 28.5 (CH2COO) 21.3 (CH3COO) ppm. 
ESI-HRMS calcd. for [C23H25N3O6 + NH4]+: 457.2081, found: 457.2082. 
 
9-{5-Azido-3-O-benzyl-2,5-dideoxy-2-C-[(benzyloxycarbonyl)methylene]-β-D-ribofuranosyl}-6-O-(diphenylcarbamoyl)-2-N-isobutyrylguanine 
(6): N,O-Bis(trimethylsilyl)acetamide (BSA) (2.23 mL, 1.85 g, 9.10 mmol, 4.00 eq.) was added under N2 to a stirred suspension of compound 21 (1.00 g, 
2.28 mmol, 1.00 eq.) and 6-O-(diphenylcarbamoyl)-2-N-isobutyrylguanine[47,48] (1.90 g, 4.55 mmol, 2.00 eq.) in dichloroethane (30 mL) and heated to 
80 °C for 30 min until a clear solution was obtained. The reaction mixture was brought to RT and treated with trimethylsilyl triflate (TMSOTf) (1.07 mL, 
1.32 g, 5.92 mmol, 2.60 eq.). The dark red solution was stirred at 80 °C for 2 h. The reaction was quenched with saturated aqueous NaHCO3 (30 mL) at 
RT and extracted with DCM (4 x 50 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue 
was purified by flash-column chromatography (silica gel, isohexanes/EtOAc, 4:12:11:1) to give nucleoside 6 (1.31 g, 1.65 mmol, 72%) as a colorless 
foam. The reaction could also be performed on a 5 g scale of the starting material 21 (yield: 59%). Rf = 0.68 (isohexanes/EtOAc = 1:1). IR (ATR): ṽ = 
3321, 2933, 2102, 1731, 1584, 1492, 1268, 1166, 1047, 694 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 7.99 (s, 1H, H-8), 7.92 (s, 1H, NH), 7.47 – 
7.18 (m, 20H, aryl-H), 6.00 (d, 3J = 8.2 Hz, 1H, H-1’), 4.94 (d, 2J = 12.3 Hz, 1H, COOCH2Ph), 4.88 (d, 2J = 12.3 Hz, 1H, COOCH2Ph), 4.58 (d, 2J = 11.6 
Hz, 1H, OCH2Ph), 4.443 (d, 2J = 11.6 Hz, 1H, OCH2Ph), 4.441 (d, 3J = 5.8 Hz, 3J = 2.1 Hz, 1H, H-3’), 4.27 – 4.21 (m, 1H, H-4’), 3.80 (dd, 2J = 13.0 Hz, 
3J = 6.3 Hz, 1H, Ha-5), 3.74 – 3.63 (m, 1H, H-2’), 3.70 (dd, 2J = 13.0 Hz, 3J = 5.3 Hz, 1H, Hb-5), 2.85 (dd, 2J = 16.7 Hz, 3J = 8.3 Hz, 1H, CH2COO), 2.80 
– 2.70 (m, 1H, CH(CH3)2), 2.48 (dd, 2J = 16.7 Hz, 3J = 6.5 Hz, 1H, CH2COO), 1.26 (s, 3H, CH(CH3)2), 1.24 (s, 3H, CH(CH3)2) ppm. 13C NMR, HSQC, 
  
 
HMBC (101 MHz, CDCl3): δ = 174.7 (CONH), 171.3 (COOBn), 156.3 (C-2), 154.6 (C-4), 151.9 (OCONPh2), 150.4 (C-6), 143.4 (C-8), 141.8 (OCON-Ph-
C1), 137.4 (OCH2Ph-C-1), 135.5 (COOCH2Ph-C-1), 129.3, 128.70, 128.67, 128.46, 128.41, 128.28, 128.17 (aryl 20C), 122.0 (C-5), 89.5 (C-1’), 82.8 (C-
4’), 80.1 (C-3’), 72.4 (OCH2Ph), 66.8 (COOCH2Ph), 52.6 (C-5’), 42.7 (C-2’), 36.5 (CH(CH3)2), 30.2 (CH2COO), 19.5 (CH(CH3)2), 19.4 (CH(CH3)2) ppm. 
ESI-HRMS calcd. for [C43H41N9O7 + H]+: 796.3202, found: 796.3214. 
 
4-{6’-Benzoylamino-9’-[2’’-O-acetyl-5’’-(tert-butoxycarbonyl)amino-3’’,5’’-dideoxy-β-D-ribofuranosyl]-9’H-purin-3’’-yl}-1-{9’’’-{3’’’’-O-benzyl-
2’’’’,5’’’’-dideoxy-2’’’’-C-[(benzyloxycarbonyl)methylene]-β-D-ribofuranosyl}-6’’’-O-(diphenylcarbamoyl)-2’’’-N-isobutyrylguanin-5’’’’-yl}-1,2,3-
triazole (22): The title compound was prepared according to a modified procedure of Singh et al.[49] A-half 5 (1.30 g, 2.50 mmol, 1.00 eq.) and G-half 6 
(2.39 g, 3.00 mmol, 1.20 eq.) were dissolved in THF/tert-BuOH/H2O (2:2:1, 80 mL) under N2 at RT. Subsequently, a solution of sodium ascorbate (0.41 g, 
2.00 mmol, 0.80 eq.) in water (3 mL) and a solution of copper(II) sulfate (0.16 g, 1.00 mmol, 0.40 eq.) in water (2 mL) was added. The mixture was stirred 
at RT for 12 h. Volatile components were evaporated and the residue was purified by flash-column chromatography (silica gel, DCM/MeOH, 
100:2100:510:1) to provide dinucleotide 22 (2.62 g, 2.00 mmol, 80%) as a colorless foam. M.p. = 183 °C (decomp.). Rf = 0.46 (DCM/MeOH = 10:1). 
IR (ATR): ṽ = 3268, 2976, 2106, 1738, 1707, 1584, 1452, 1216 1167, 732 cm−1. 1H NMR, COSY (400 MHz, CDCl3): δ = 9.14 (s, 1H, NHBz), 8.86 (s, 1H, 
H-2‘), 8.25 (s, 1H, NHiBu), 8.09 (s, 1H, H-8‘), 8.02 (d, 3J = 7.6 Hz, 1H, Bz-o-CH), 7.85 (s, 1H, H-8‘‘‘), 7.82 (s, 1H, H-5), 7.62 – 7.56 (m, 1H, Bz-p-CH), 
7.50 (t, 3J = 7.6 Hz, 2H, Bz-m-CH), 7.48 – 7.12 (m, 20H, aryl-H), 6.81 (dd, 3J = 7.3 Hz, 4J = 3.2 Hz, 1H, NHBoc), 6.19 (d, 3J = 3.9 Hz, 1H, H-1‘‘), 5.95 (d, 
3J = 8.2 Hz, 1H, H-1‘‘‘‘), 5.71 (dd, 3J = 7.3 Hz, 3J = 3.9 Hz, 1H, H-2‘‘), 5.15 (dd, 2J = 14.0 Hz, 3J = 6.5 Hz, 1H, Ha-5’’’’), 4.93 (dd, 2J = 14.0 Hz, 3J = 8.0 Hz, 
1H, Hb-5’’’’), 4.88 (d, 2J = 12.3 Hz, 1H, COOCH2Ph), 4.87 – 4.83 (m, 1H, H-4’’’’), 4.83 – 4.78 (m, 1H, H-4‘‘), 4.79 (d, 2J = 12.3 Hz, 1H, COOCH2Ph), 4.61 
(d, 2J = 11.6 Hz, 1H, OCH2Ph), 4.40 (d, 3J = 5.3 Hz, 1H, H-3’’’’), 4.37 – 4.32 (m, 1H, H-3’’), 4.32 (d, 2J = 11.6 Hz, 1H, OCH2Ph), 4.15 – 4.04 (m, 1H, H-
2’’’’), 3.61 – 3.51 (m, 1H, Ha-5’’), 3.53 – 3.44 (m, 1H, Hb-5’’), 2.80 (dd, 2J = 16.6 Hz, 3J = 8.3 Hz, 1H, CH2COO), 2.59 (hept, 3J = 6.9 Hz, 1H, CH(CH3)2), 
2.45 (dd, 2J = 16.7 Hz, 3J = 7.1 Hz, 1H, CH2COO), 1.70 (s, 3H, OCOCH3), 1.45 (s, 9H, C(CH3)3), 1.25, (d, 3J = 6.9 Hz, 3H, CH(CH3)2), 1.21, (d, 3J = 6.9 
Hz, 3H, CH(CH3)2) ppm. 13C NMR, HSQC, HMBC (101 MHz, CDCl3): δ = 174.3 (iBu-CONH), 171.0 (COOBn), 169.8 (OCOCH3), 164.7 (N-CO-Ph), 156.7 
(N-CO-OC(CH3)3), 156.4 (C-2‘‘‘), 154.1 (C-4‘‘‘), 152.7 (C-2‘), 151.6 (OCONPh2), 151.1 (C-4‘), 150.4 (C-6‘), 150.1 (C-6‘‘‘), 144.4 (C-8‘‘‘), 142.7 (C-8‘), 
141.7 (OCON-Ph2-C1), 140.7 (C-4), 137.1 (OCH2Ph-C-1), 135.4 (COOCH2Ph-C-1), 133.5 (Bz-C-CO-N), 133.0 (Bz-p-CH), 129.3, 129.0, 128.61, 128.55, 
128.42, 128.25, 128.17, 128.03, 127.98 (aryl 25C), 125.2 (C-5), 124.2 (C-5‘), 122.8 (C-5‘‘‘), 90.9 (C-1‘‘‘‘), 90.2 (C-1‘‘), 83.3 (C-4‘‘), 82.1 (C-4‘‘‘‘), 79.6 (C-
3‘‘‘‘), 79.4 (C(CH3)3), 77.1 (C-2‘‘), 71.8 (OCH2Ph), 66.7 (COOCH2Ph), 51.2 (C-5‘‘‘‘), 42.4 (C-5‘‘), 40.5 (C-2‘‘‘‘), 39.9 (C-3‘‘), 36.9 (CH(CH3)2), 30.3 
(CH2COO), 28.6 (C(CH3)3), 20.3 (OCOCH3), 19.5 (CH(CH3)2), 19.40 (CH(CH3)2) ppm. ESI-HRMS calcd. for [C69H69N15O13 + H]+: 1316.5272, found: 
1316.5330. ESI-HRMS calcd. for [C69H69N15O13 + Na]+: 1338.5091, found: 1338.5151. 
 
 
 
4-[6’-Benzoylamino-9’-(2’’-O-acetyl-5’’-amino-3’’,5’’-dideoxy-β-D-ribofuranosyl)-9’H-purin-3’’-yl]-1-{9’’’-[3’’’’-O-benzyl-2’’’’,5’’’’-dideoxy-2’’’’-C-
carboxymethyl-β-D-ribofuranosyl]-2’’’-N-isobutyrylguanin-5’’’’-yl}-2’’’’,5’’-lactame-1,2,3-triazole (24): To a stirred solution of dinucleotide 22 (2.12 g, 
1.61 mmol, 1.00 eq.) in dry DCM (40 mL) was added TFA (20 mL) at 0 °C under N2. The mixture was stirred for 1 h at this temperature and then 
concentrated in vacuo. The brown residue was purified by flash-column chromatography (silica gel, DCM/MeOH, 100:2100:5 5:1) to give amino 
compound 23 as a colorless solid (1.33 g, 1.30 mmol, 81%). M.p. = 128 °C (decomp.). Rf = 0.39 (DCM/MeOH = 5:1). ESI-HRMS calcd. for [C51H52N14O10 
+ H]+: 1021.4064, found: 1021.4038. ESI-HRMS calcd. for [C51H52N14O10 – H]-: 1019.3918, found: 1019.3918. 
To a solution of amino compound 23 (1.08 g, 1.06 mmol, 1.00 eq.) in EtOH (50 mL) was added Pd/C (10 wt.%, 0.30 g) under nitrogen stream at RT. The 
reaction vessel was evacuated and flushed with hydrogen three times. The mixture was stirred under hydrogen atmosphere for 36 h and then filtered 
through celite. The solution was concentrated to dryness under reduced pressure. The residue was used in the next step without further purification. ESI-
HRMS calcd. for [C44H46N14O10 + H]+: 931.3594, found: 931.3594. ESI-HRMS calcd. for [C44H46N14O10 – H]-: 929.3448, found: 929.3450. 
Finally, the title compound was prepared according to a modified procedure of Horne et al.[50] and Kinzie et al.[51] To a yellow solution of the hydrogenated 
compound 23 and HATU (0.60 g, 1.58mmol, 1.50 eq.) in dry DMF (1000 mL) was added DIPEA (0.72 mL, 0.54 g, 4.21 mmol, 4.00 eq.) at RT. The 
solution turned orange and was stirred at RT for 24 h. After addition of MeOH (5 mL), volatile materials were removed under reduced pressure and the 
crude product was purified by flash-column chromatography (silica gel, DCM/MeOH, 100:2100:55:1) to yield cyclized compound 24 as a colorless 
solid (506 mg, 0.55 mmol, 52% over 2 steps). An analytical sample was provided by RP-HPLC. M.p. = 185 °C (decomp.). Rf = 0.57 (DCM/MeOH = 5:1). 
Rt = 16.1 min (RP-HPLC, 15% to 80% MeCN gradient elution). IR (ATR): ṽ = 3220, 1682, 1608, 1454, 1403, 1222, 1049, 797, 708 cm−1. 1H NMR, COSY, 
NOESY (600 MHz, DMSO-d6): δ = 12.06 (s, 1H, NH), 11.59 (s, 1H, NH), 11.27 (s, 1H, NH), 8.83 (s, 1H, H-2‘), 8.68 (s, 1H, H-8‘), 8.54 (s, 1H, H-5), 8.35 
(s, 1H, H-8‘‘‘), 8.08 – 8.03 (m, 2H, Bz-o-CH), 8.06 – 8.03 (s, 1H, CH2CONHCH2), 7.68 – 7.63 (m, 1H, Bz-p-CH), 7.59 – 7.53 (m, 2H, Bz-m-CH), 7.52 – 
7.49 (m, 2H, Bn-o-CH), 7.44 – 7.40 (m, 2H, Bn-m-CH), 7.38 – 7.34 (m, 1H, Bn-p-CH), 6.46 (d, 3J = 1.1 Hz, 1H, H-1‘‘), 5.92 (dd, 3J = 5.9 Hz, 3J = 1.1 Hz, 
1H, H-2‘‘), 5.66 (d, 3J = 10.2 Hz, 1H, H-1‘‘‘‘), 4.85 (dd, 2J = 15.0 Hz, 3J = 3.3 Hz, 1H, Ha-5’’’’), 4.80 – 4.77 (m, 1H, Hb-5’’’’), 4.80 (d, 2J = 10.9 Hz, 1H, 
OCH2Ph), 4.76 (dd, 3J = 10.6 Hz, 3J = 6.0 Hz, 1H, H-3’’), 4.68 (d, 2J = 10.9 Hz, 1H, OCH2Ph), 4.68 – 4.66 (m, 1H, H-4’’’’), 4.57 (td, 3J = 10.5 Hz, 3J = 4.1 
Hz, 1H, H-4‘‘), 4.15 (d, 3J = 3.4 Hz, 1H, H3‘‘‘‘), 3.87 – 3.81 (m, 1H, Ha-5’’), 2.91 – 2.83 (m, 1H, Hb-5’’), 2.67 (hept, 3J = 6.9 Hz, 1H, CH(CH3)2), 2.11 (s, 
3H, OCOCH3), 2.04 (t, 3J = 12.0 Hz, 1H, CH2CONH), 1.76 – 1.70 (m, 1H, CH2CONH), 1.07, (d, 3J = 6.9 Hz, 3H, CH(CH3)2), 1.06, (d, 3J = 6.9 Hz, 3H, 
CH(CH3)2), -0.19 – -0.26 (m, 1H, H-2‘‘‘‘) ppm. 13C NMR, HSQC, HMBC (151 MHz, DMSO-d6): δ = 180.1 (iBu-CONH), 170.8 (CH2CONHCH2), 169.1 
(OCOCH3), 165.7 (N-CO-Ph), 154.8 (C-2‘‘‘), 151.8 (C-2‘), 151.5 (C-4‘), 150.7 (C-6‘), 149.1 (C-6‘‘‘), 148.30 (C-4‘‘‘), 144.0 (C-8‘), 142.8 (C-4), 138.2 
(OCH2Ph-C-1), 137.9 (C-8‘‘‘), 133.3 (Bz-C-CO-N), 132.5 (Bz-p-CH), 128.53 (Bz-o-CH), 128.49 (Bz-m-CH), 128.47 (Bn-m-CH), 128.3 (Bn-o-CH), 127.9 
(Bn-p-CH), 126.8 (C-5), 126.2 (C-5‘), 119.7 (C-5‘‘‘), 89.3 (C-1‘‘), 83.3 (C-1‘‘‘‘), 81.2 (H-4‘‘), 79.9 (H-3‘‘‘‘), 79.8 (H-4‘‘‘‘), 77.5 (C-2‘‘), 72.0 (OCH2Ph), 53.0 
(C-5‘‘‘‘), 46.9 (C-2‘‘‘‘), 44.5 (C-3‘‘), 42.4 (C-5‘‘), 34.7 (CH(CH3)2), 29.7 (CH2CONH), 20.7 (OCOCH3), 18.81 (CH(CH3)2), 18.79 (CH(CH3)2) ppm. ESI-HRMS 
calcd. for [C44H44N14O9 + H]+: 913.3489, found: 913.3495. ESI-HRMS calcd. for [C44H44N14O9 - H]-: 911.3343, found: 911.3348. 
 
4-[6’-Benzoylamino-9’-(2’’-O-acetyl-5’’-amino-3’’,5’’-dideoxy-β-D-ribofuranosyl)-9’H-purin-3’’-yl]-1-{9’’’-[2’’’’,5’’’’-dideoxy-2’’’’-C-carboxymethyl-
β-D-ribofuranosyl]-2’’’-N-isobutyrylguanin-5’’’’-yl}-2’’’’,5’’-lactame-1,2,3-triazole (25): To a solution of dinucleotide 24 (340 mg, 0.37 mmol, 1.00 eq.) 
in dry DCM (300 mL) was added BCl3 (5.96 mL, 5.96 mmol, 1M in DCM, 16.0 eq.) at -40°C. The mixture was stirred for 3 days at this temperature, 
quenched by addition of MeOH (5 mL) and extracted with saturated sodium bicarbonate (20 mL) and DCM (4 x 50 mL). The combined organic layers 
were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The compound was used in the next step without further purification. An analytical 
sample was prepared by RP-HPLC to yield a colorless solid. M.p. = 258 °C (decomp.). Rt = 12.5 min (RP-HPLC, 15% to 80% MeCN gradient elution). 
IR (ATR): ṽ = 3234, 1756, 1677, 1613, 1460, 1403, 1220, 1047, 796, 707 cm−1. 1H NMR, COSY, NOESY (600 MHz, DMSO-d6): δ = 12.07 (s, 1H, NH), 
11.69 (s, 1H, NH), 11.26 (s, 1H, NH), 8.82 (s, 1H, H-2‘), 8.66 (s, 1H, H-8‘), 8.43 (s, 1H, H-5), 8.33 (s, 1H, H-8‘‘‘), 8.08 – 8.03 (m, 1H, Bz-o-CH), 7.93 – 
7.87 (m, 1H, CH2CONHCH2), 7.68 – 7.63 (m, 1H, Bz-p-CH), 7.59 – 7.53 (m, 2H, Bz-m-CH), 6.42 (d, 3J = 1.1 Hz, 1H, H-1‘‘), 5.88 (dd, 3J = 5.9 Hz, 3J = 
  
 
1.1 Hz, 1H, H-2‘‘), 5.76 (d, J = 10.2 Hz, 1H, H-1‘‘‘‘), 5.68 (d, J = 3.4 Hz, 1H, OH-3‘‘‘‘), 4.78 (dd, 2J = 15.0 Hz, 3J = 3.3 Hz, 1H, Ha-5’’’’), 4.71 (dd, 3J = 10.6 
Hz, 3J = 6.0 Hz, 1H, H-3’’), 4.68 (dd, 2J = 15.0 Hz, 3J = 1.8 Hz, 1H, Hb-5’’’’), 4.50 (td, 3J = 10.4 Hz, 3J = 3.9 Hz, 1H, H-4‘‘), 4.32 – 4.29 (m, 1H, H-4’’’’), 
4.17 – 4.13 (m, 1H, H3‘‘‘‘), 3.82 – 3.74 (m, 1H, Ha-5’’), 2.89 – 2.79 (m, 1H, Hb-5’’), 2.73 (hept, 3J = 6.8 Hz, 1H, CH(CH3)2), 2.09 (s, 3H, OCOCH3), 2.02 (t, 
3J = 12.0 Hz, 1H, CH2CONH), 1.67 – 1.60 (m, 1H, CH2CONH), 1.11, (d, 3J = 6.8 Hz, 3H, CH(CH3)2), 1.10, (d, 3J = 6.8 Hz, 3H, CH(CH3)2), -0.39 – -0.49 
(m, 1H, H-2‘‘‘‘) ppm. 13C NMR, HSQC, HMBC (151 MHz, DMSO-d6): δ = 180.1 (iBu-CONH), 171.0 (CH2CONHCH2), 169.2 (OCOCH3), 165.7 (N-CO-Ph), 
154.8 (C-2‘‘‘), 151.8 (C-2‘), 151.5 (C-4‘), 150.7 (C-6‘), 149.1 (C-6‘‘‘), 148.30 (C-4‘‘‘), 144.0 (C-8‘), 142.6 (C-4), 138.2 (C-8‘‘‘), 133.3 (Bz-C-CO-N), 132.5 
(Bz-p-CH), 128.52 (Bz-o-CH), 128.49 (Bz-m-CH), 126.6 (C-5), 126.2 (C-5‘), 119.7 (C-5‘‘‘), 89.3 (C-1‘‘), 83.2 (C-1‘‘‘‘),83.0 (C-4‘‘‘‘), 81.0 (C-4‘‘), 77.4 (C-
2‘‘), 70.6 (C-3‘‘‘‘), 52.5 (C-5‘‘‘‘), 47.1 (C-2‘‘‘‘), 44.5 (C-3‘‘), 42.5 (C-5‘‘), 34.8 (CH(CH3)2), 29.2 (CH2CONH), 20.6 (OCOCH3), 18.85 (CH(CH3)2), 18.83 
(CH(CH3)2) ppm. ESI-HRMS calcd. for [C37H38N14O9 + H]+: 823.3019, found: 823.3015. ESI-HRMS calcd. for [C37H38N14O9 - H]-: 821.2873, found: 
821.2873. 
 
4-[6’-Amino-9’-(5’’-amino-3’’,5’’-dideoxy-β-D-ribofuranosyl)-9’H-purin-3’’-yl]-1-{9’’’-[2’’’’,5’’’’-dideoxy-2’’’’-C-carboxymethyl-β-D-ribofuranosyl]-
guanin-5’’’’-yl}-2’’’’,5’’-lactame-1,2,3-triazole (4): The crude compound 25 was dissolved in MeOH (15 mL) and aqueous ammonia (25%, 15 mL) in a 
sealed vessel at RT. The mixture was stirred at 50 °C for 20 h. Volatile components were removed under reduced pressure. The residue was purified by 
preparative RP-HPLC to provide the final compound 4 as a colorless solid (109 mg, 0.18 mmol, 48% over 2 steps). M.p. = 270 °C (decomp.). Rt = 7.8 
min (RP-HPLC, 15% to 80% MeCN gradient elution). IR (ATR): ṽ = 3338, 1639, 1599, 1477, 1419, 1209, 1089, 1047, 1005, 730 cm−1. 1H NMR, COSY, 
NOESY (600 MHz, DMSO-d6): δ = 10.60 (s, 1H, Guanine-NH), 8.34 (s, 1H, H-8‘), 8.19 (s, 1H, H-2‘), 8.12 (s, 1H, H-5), 8.07 (s, 1H, H-8‘‘‘), 7.73 – 7.69 
(m, 1H, CH2CONHCH2), 7.32 (s, 2H, A-NH2), 6.50 (s, 2H, G-NH2), 6.07 (d, 3J = 1.1 Hz, 1H, H-1‘‘), 5.97 (d, 3J = 5.1 Hz, 1H, H-2‘‘), 5.64 (d, J = 10.3 Hz, 
1H, H-1‘‘‘‘), 5.58 (d, J = 3.6 Hz, 1H, OH-3‘‘‘‘), 4.77 (dd, 2J = 14.9 Hz, 3J = 3.1 Hz, 1H, Ha-5’’’’), 4.65 – 4.62 (m, 1H, OH-2’’), 4.61 (dd, 2J = 14.9 Hz, 3J = 
1.5 Hz, 1H, Hb-5’’’’), 4.43 (td, 3J = 10.5 Hz, 3J = 4.1 Hz, 1H, H-4‘‘), 4.23 – 4.21 (m, 1H, H-4’’’’), 4.23 (dd, 3J = 10.6 Hz, 3J = 5.6 Hz, 1H, H-3’’), 4.10 – 4.07 
(m, 1H, H-3‘‘‘‘), 3.77 – 3.71 (m, 1H, Ha-5’’), 2.84 – 2.77 (m, 1H, Hb-5’’), 1.97 (m, 1H, CH2CONH), 1.56 (dd, 2J = 12.0 Hz, 3J = 2.2 Hz,1H, CH2CONH), -
0.44 – -0.41 (m, 1H, H-2‘‘‘‘) ppm. 13C NMR, HSQC, HMBC (151 MHz, DMSO-d6): δ = 170.9 (CH2CONHCH2), 156.8 (C-2‘‘‘), 156.2 (C-6‘), 153.8 (C-6‘‘‘), 
152.6 (C-2‘), 151.7 (C-4‘‘‘), 148.7 (C-4‘), 143.7 (C-4), 139.81 (C-8‘), 136.0 (C-8‘‘‘), 126.8 (C-5), 119.5 (C-5‘), 116.1 (C-5‘‘‘), 91.9 (C-1‘‘), 83.7 (C-4‘‘‘‘), 82.7 
(C-1‘‘‘‘), 80.8 (C-4‘‘), 75.9 (C-2‘‘), 70.6 (C-3‘‘‘‘), 52.2 (C-5‘‘‘‘), 46.7 (C-2‘‘‘‘), 45.9 (C-3‘‘), 42.7 (C-5‘‘), 29.3 (CH2CONH) ppm. ESI-HRMS calcd. for 
[C24H26N14O6 + H]+: 607.2233, found: 607.2231. ESI-HRMS calcd. for [C24H26N14O6 - H]-: 605.2087, found: 605.2090. 
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Compound 24 (COSY, 600 MHz, DMSO-d6) 
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Compound 24 (HSQC, 600 MHz, DMSO-d6)  
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Compound 25 (1H-NMR, 600 MHz, DMSO-d6) 
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Compound 25 (COSY, 600 MHz, DMSO-d6) 
 
Compound 25 (NOESY, 600 MHz, DMSO-d6) 
 
1H-/13C-NMR SPECTRA OF THE SYNTHESIZED COMPOUNDS 
 
Compound 25 (HSQC, 600 MHz, DMSO-d6)  
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Compound 4 (1H-NMR, 600 MHz, DMSO-d6) 
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Compound 4 (COSY, 600 MHz, DMSO-d6) 
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Compound 4 (HSQC, 600 MHz, DMSO-d6)  
 
Compound 4 (HMBC, 600 MHz, DMSO-d6)  
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Temperature dependent 1H-NMR of compound 4 in DMSO-d6 
 
Chemical shift of H-2‘‘‘‘ 
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2. RP-HPLC 
The purification of compound 24, 25 and 4 was performed by reversed-phase HPLC. 
The crude products were dissolved in 30% MeCN, respectively. 
 
Preparative RP-HPLC (flow rate: 5 mL/min) 
T / min 0 15 17 22 24 30 
A (H2O) / % 85 80 20 20 85 85 
B (MeCN) / % 15 20 80 80 15 15 
 
Product fractions were collected from 23.0 – 25.0 min for 24, 11.5 – 13.5 min for 25 
and 7.5 – 9.5 min for 4, respectively. Solvents were evaporated and the compounds 
were lyophilized overnight to give colorless solids. 
 
Analytical RP-HPLC (flow rate: 0.5 mL/min) was conducted with a stronger gradient. 
T / min 0 15 17 22 24 30 
A (H2O) / % 85 20 20 20 85 85 
B (MeCN) / % 15 80 80 80 15 15 
 
Rt (compound 24) = 16.1 min 
Rt (compound 25) = 12.5 min 
Rt (compound 4) = 7.8 min 
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Analytical RP-HPLC (15% to 80% MeCN gradient elution) 
 
Compound 24: 
 
 
Compound 25: 
 
 
Compound 4: 
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X-RAY CRYSTALLOGRAPHY   
 
3. X-ray crystallography data 
 
Compound 10d: 
 
 
net formula C17H20O6S 
Mr/g mol−1 352.39 
crystal size/mm 0.080 × 0.050 × 0.030 
T/K 103.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorombic 
space group 'P 21 21 21' 
a/Å 5.5797(3) 
b/Å 16.2174(7) 
c/Å 18.6761(8) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1689.97(14) 
Z 4 
calc. density/g cm−3 1.385 
μ/mm−1 0.221 
absorption correction Multi-Scan 
transmission factor range 0.92–0.99 
refls. measured 17954 
Rint 0.0404 
mean σ(I)/I 0.0305 
θ range 3.327–27.090 
observed refls. 3480 
x, y (weighting scheme) 0.0355, 0.4445 
hydrogen refinement constr 
Flack parameter −0.01(3) 
refls in refinement 3706 
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parameters 220 
restraints 0 
R(Fobs) 0.0290 
Rw(F2) 0.0724 
S 1.041 
shift/errormax 0.001 
max electron density/e Å−3 0.236 
min electron density/e Å−3 −0.366 
 
 
Compound 11: 
 
 
net formula C11H13N3O5 
Mr/g mol−1 267.24 
crystal size/mm 0.080 × 0.050 × 0.030 
T/K 103.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21 1' 
a/Å 10.1530(7) 
b/Å 7.0554(5) 
c/Å 18.1171(13) 
α/° 90 
β/° 101.769(2) 
γ/° 90 
V/Å3 1270.51(16) 
Z 4 
calc. density/g cm−3 1.397 
μ/mm−1 0.112 
absorption correction Multi-Scan 
transmission factor range 0.94–1.00 
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refls. measured 13325 
Rint 0.0382 
mean σ(I)/I 0.0460 
θ range 3.376–26.363 
observed refls. 4785 
x, y (weighting scheme) 0.0337, 0.2537 
hydrogen refinement constr 
Flack parameter −0.6(5) 
refls in refinement 5174 
parameters 347 
restraints 1 
R(Fobs) 0.0344 
Rw(F2) 0.0821 
S 1.041 
shift/errormax 0.001 
max electron density/e Å−3 0.188 
min electron density/e Å−3 −0.183 
 
Correct structure derived from synthesis. 
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Compound 18: 
 
 
net formula C15H18O7S 
Mr/g mol−1 342.35 
crystal size/mm 0.444 × 0.148 × 0.141 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'P 21' 
a/Å 11.1971(7) 
b/Å 5.8612(3) 
c/Å 12.8844(8) 
α/° 90 
β/° 112.211(7) 
γ/° 90 
V/Å3 782.84(9) 
Z 2 
calc. density/g cm−3 1.452 
μ/mm−1 0.241 
absorption correction multi-scan 
transmission factor range 0.90050–1.00000 
refls. measured 4714 
Rint 0.0268 
mean σ(I)/I 0.0502 
θ range 4.541–26.367 
observed refls. 2507 
x, y (weighting scheme) 0.0348, 0.1576 
X-RAY CRYSTALLOGRAPHY   
 
hydrogen refinement constr 
Flack parameter −0.04(7) 
refls in refinement 2844 
parameters 210 
restraints 1 
R(Fobs) 0.0413 
Rw(F2) 0.0926 
S 1.029 
shift/errormax 0.001 
max electron density/e Å−3 0.249 
min electron density/e Å−3 −0.252 
 
 
 
BINDING EVALUATION OF COMPOUND 4 TO STING in vitro  
 
 
4. Binding evaluation of compound 4 to STING in vitro 
 
 
 
Figure S1: Compound 4 is not binding to STING in vitro. 
(A) DSF thermal shift first derivative of 5 µM hSTING_L139 (orange), 5 µM hSTING_L139 + 50 µM 2′3′-cGAMP (red), 3′3′-
cGAMP (blue), 50 µM 4 (dark green) and 150 µM 4 (light green). 
(B) DSF thermal shift first derivative of 5 µM mSTING_L138 (orange), 5 µM mSTING_L139 + 50 µM 2′3′-cGAMP (red), 3′3′-
cGAMP (blue), 50 µM 4 (dark green) and 150 µM 4 (light green). 
(C) ITC measurement raw data of 20 µM hSTING_L139 titrated with 291 µM 4. 
(D) ITC measurement raw data of 20 µM mSTING_L138 titrated with 291 µM 4 
